Enhancing efficacy of oncolytic myxoma virus and adoptive T cell therapy against tumors by Tosic, Vesna
ENHANCING EFFICACY OF ONCOLYTIC MYXOMA VIRUS AND ADOPTIVE T CELL 
THERAPY AGAINST TUMORS 
BY 
 
VESNA TOSIC 
DISSERTATION 
 
Submitted in partial fulfillment of the requirements 
for the degree of Doctor of Philosophy in Molecular and Integrative Physiology 
in the Graduate College of the 
University of Illinois at Urbana-Champaign, 2015 
Urbana, Illinois 
Doctoral Committee: 
 
 Professor Edward J. Roy, Chair 
 Professor Milan K. Bagchi 
 Professor David M. Kranz 
 Associate Professor Joanna L. Shisler  
 Associate Professor Lori T. Raetzman 
  
ii 
ABSTRACT 
Immunotherapy in general and adoptive cell transfer in particular have recently been in the 
spotlight of cancer research. Recent FDA approval of the first immunotherapeutic drugs and 
promising results in clinical trials suggest that this therapeutic modality holds great promise in 
fighting cancers. Another attractive strategy is oncolytic viral therapy, the use of cancer-specific 
viruses to target and kill cancer cells. Combining immunotherapies and viral therapies has shown 
synergistic effect in the past. 
Most of our work focused on myxoma virus, a rabbit poxvirus, which can efficiently infect various types 
of mouse and human cancer cells. It is a strict rabbit-specific pathogen, and is thought to be safe as a 
therapeutic agent in all non-rabbit hosts tested including mice and humans.  
Chapter 1 introduces concepts of immune system and cancer interaction, gives an overview of current 
immunotherapy strategies, describes the current state of oncolytic viral therapy, and ends with discussion 
on myxoma virus as a gene delivery agent for cancer therapy.  
In chapter 2, we describe engineering a new recombinant myxoma virus (vMyx-IL15Rα-tdTr), which 
expresses an IL15Rα-IL15 fusion protein as well as tdTomato red fluorescent reporter protein, and the 
antitumor effect of the virus. Interleukin-15 (IL15) is an immunomodulatory cytokine with significant 
potential for stimulating anti-tumor T lymphocytes and NK cells. Co-expression of IL15 with the α subunit 
of IL15 receptor (IL15Rα) greatly enhances IL15 stability and bioavailability. Our findings demonstrated 
successful expression of the introduced proteins in cells infected by the modified virus in culture. In the 
animal tumor models, the novel IL15Rα-IL15 fusion protein expressing virus showed increased antitumor 
activity compared to non-modified virus and other controls in both RAG1-/- mice that lack B and T cells 
and in fully immunocompetent C57BL/6 mice. We showed by immunostaining that both natural killer (NK) 
cells and T cells likely play a role in the increased antitumor effect of vMyx-IL15Rα-tdTr. 
In chapter 3, potential combination therapy of the oncolytic myxoma virus and adoptive T cell therapy was 
further evaluated. Combination therapy of previously characterized vMyx-IL15Rα-tdTr and naïve or tumor-
antigen specific activated T cells conveyed some antitumor protection, but the effect of combination 
treatment was not statistically significant. Increasing the levels of tumor-associated antigens in the context 
of dying cancer cells sensitizes supporting cells in the tumor to reverse immunosuppression and prime 
antitumor adaptive immune response. We hypothesized that myxoma virus with its specificity for cancer 
cells could be a delivery vehicle for increasing the tumor-associated antigens at the tumor site. In order to 
test that hypothesis, we conducted initial steps in generating a new recombinant myxoma virus, vMyx-SIY-
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tdTr, for exploring possibilities of combination therapy with the 2C T cell – SIY tumor antigen model 
system.  
In chapter 4, we further evaluated the nature of the side effect of the adoptive T cell therapy in our preclinical 
model. It was noticed earlier that some tumor bearing mice treated with genetically engineered CD4+ T cells 
developed graft-versus-host disease (GVHD) symptoms. Occurrence of these side effects is a clinically 
relevant phenomenon, and understanding their basis is important for improving the safety of adoptive T 
cell therapies. We investigated the incidence and cellular mechanism of these symptoms in experimental 
mice.  
Overall, our work showed the feasibility of using an oncolytic/oncotropic virus as a delivery agent to 
additionally boost innate and adaptive immune system against cancer. Novel viral engineering strategies 
and therapy combinations may improve the viral as well as the immune antitumor effect. Our work has 
contributed to understanding the efficacy and safety of clinically relevant therapeutic approaches.  
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CHAPTER ONE 
INTRODUCTION 
1.1 Cancer and immune system 
Immunotherapy is emerging as one of the most promising strategies against cancer. FDA approval of two 
immunotherapies, Sipuleucel-T against prostate cancer in 2010 and ipilimumab against melanoma in 2011, 
has driven immunotherapy to the spotlight of cancer research [1] [2]. Cancer immunotherapy was 
highlighted as the breakthrough of the year 2013 by the Science Magazine [3]. However, until not that long 
ago, skepticism about the ability of immune system to recognize cancer, let alone have the curative 
potential, was prevalent in scientific circles [4].  
History of cancer immunotherapy 
Dr. William Coley, a bone surgeon and cancer researcher from late 19th century New York, is considered 
to be the pioneer of cancer immunotherapy. Based on observations from historical records and previous 
researchers, he did clinical experiments in which he injected live Streptococcus pyogenes organisms in 
tumors of patients, some of whom experienced complete recovery. He later developed “Coley’s toxin” – a 
vaccine adjuvant that contained a combination of two killed bacterial strains [5]. It is difficult to gauge the 
effectiveness of the early Coley’s toxin because of less stringent standards of conducting clinical trials and 
scientific reporting at the time. However, it was used to treat patients with a variety of types of cancer up 
until the early 1950s, and some retrospective studies showed that overall survival of Coley’s patients was 
comparable to modern conventional treatments [6] [7]. Coley’s initiative to boost the immune system to 
fight cancer was supplanted by James Ewing and the emergence of radiotherapy starting from 1901, which 
remained the mainstream in cancer therapy for more than a 100 years [8]. With the incorporation of 
antiseptic surgical techniques in the late 1800s, establishment of radiotherapy and chemotherapy that could 
be more easily standardized than Coley’s toxin, and increased use of antibiotics, empowerment of immune 
system to aid in tumor regression was considerably reduced in mainstream cancer treatment [8].  
The suggestion that the immune system plays a role in tumor recognition and control gained new 
momentum in 1970s, with the emergence of the concept of immunosurveillance of cancer by Burnet and 
Thomas [9] [10]. They suggested that the immune system may protect the host from tumor development 
[11]. However, this hypothesis was temporarily brought into question by experiments showing that there 
was no difference in tumor growth rate between nude (T cell deficient) and wild type mice [12]. It was not 
until mouse models with more complete deficiency of the immune system were developed, that it was 
convincingly shown that various components of immune system have a role in tumor establishment, control 
and eventual disease presentation [13].  
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Cancer immunoediting 
Robert Schreiber adapted the concept of immunosurveillance into a more general process of cancer 
immunoediting. This concept encompasses tumor elimination as well as sculpting the immunogenic 
phenotypes of tumors that eventually form in immunocompetent hosts [11]. The three E’s of cancer 
immunoediting that describe cancer and immune system interplay are: elimination, equilibrium and escape. 
Elimination corresponds to immunosurveillance; equilibrium is the process in which the immune system 
puts selective pressure on tumor cell variants, rendering some of them capable to eventually survive 
immune attack; escape is the process in which tumor previously influenced by the immune system expands 
in an uncontrolled manner in the host [13].  
Multiple components of the host immune system play roles in cancer immunoediting. In the initial steps of 
the elimination phase, lymphocytes of the innate (non-specific) immune response (NKT, NK and γδ T cells) 
recognize transformed cells and produce an immunostimulatory cytokine, IFNγ [14] [15]. Initial release of 
IFNγ further stimulates innate immune reactions, such as induction of chemokines that block 
neovascularization in the tumor, recruitment of NK cells, dendritic cells and macrophages to the tumor site, 
and killing of tumor cells by macrophages, NK cells and other mechanisms [16] [17] [18]. These actions 
result in some tumor cell death and in transport of tumor cell components to the draining lymph nodes by 
dendritic cells [19]. In the lymph node, the adaptive (specific) component of the immune system is raised: 
tumor-specific CD4+ and CD8+ T cells are recruited [20]. Subsequently, T cells travel to the tumor along a 
chemokine gradient, where they specifically recognize and destroy cells bearing antigenic peptides they 
have specificity for [21]. Another component of the adaptive immune system that may play a role in 
immunosurveillance is the humoral response, with antibodies capable of recognizing potentially mutated 
cancer-specific proteins expressed on the surface of the cell, and mounting an antibody-dependent cell 
killing response [22].  
Mechanisms of tumor immunosuppression 
Tolerance mechanisms are characterized by the absence of an immune response to a specific set of antigens 
and maintenance of normal responses to all other antigens. These mechanisms are directed against the 
antitumor activity elicited by cells of adaptive immune system, mainly the Th1 subpopulation of CD4+ 
helper T cells and CD8+ cytotoxic T lymphocytes (CTLs) [23]. Examples of tolerance mechanisms induced 
by tumor cells include secretion of decoy receptors that bind and neutralize Fas ligand (FasL, death receptor 
ligand on T cells) [24], deletion of T cells by expression of death-inducing ligands on tumor cells [25], 
secretion of suppressive transforming growth factor-β (TGFβ) [26], inducing T cell anergy and deficient 
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priming etc. These processes yield to reduced or completely suppressed cytolytic activity of intratumoral 
effector T cells.  
Additional immunosuppression mechanisms are characterized by an impaired ability of the immune system 
to fight cancer development, mediated by suppressive cell populations within the tumor environment, 
including tumor associated macrophages (TAMs), myeloid derived suppressor cells (MDSCs), and 
regulatory T cells (Tregs) [23]. TAMs are a subset of macrophages that are activated towards a non-
cytotoxic phenotype (M2 phenotype) [27]. They are present in the tumor environment, where they promote 
tumor-specific neoangiogenesis, secrete growth factors, as well as immunosuppressive cytokines like IL10 
[28]. MDSCs are a heterogeneous cell population of incompletely matured granulocytes, macrophages and 
dendritic cells [29]. They can inactivate both CD4+ and CD8+ T cells, by mechanisms such as: 
overexpressing CD80 (B7-1), a ligand for the inhibitory molecule CTLA-4, producing the enzyme arginase, 
producing high levels of ROS and NO [30]. Tregs (CD4+CD25+FoxP3+ T cells) suppress antitumor immune 
response through high surface expression of CTLA-4, activation of the FoxP3 transcription factor, secretion 
of IL10 and other mechanisms [31].  
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1.2 Current approaches in cancer immunotherapy 
Current immunotherapy strategies include monoclonal antibodies against tumor cells or immune-regulatory 
molecules, cancer vaccines, cytokines and cell-based therapies such as adoptive transfer of T cells [32]. 
Monoclonal antibodies 
Monoclonal antibodies were one of the first promising immunotherapy strategies. When hybridoma 
technology, invented by Kohler and Milstein in 1975, made production of monoclonal antibodies possible, 
hopes were high that antibodies were the “magic bullet” that would cure all cancers, as first proposed by 
Paul Ehrlich in 1906 [33]. Unfortunately, the clinical applicability of these first monoclonal antibodies was 
limited since they were made in mice; they were immunogenic in humans and had poor abilities to induce 
human effector responses. Advances in antibody engineering provided the possibility to make chimeric, 
humanized and fully human monoclonal antibodies that addressed many of these early issues [34]. 
In the past decade, the clinical relevance of antibodies has been evident by FDA approval of more than ten 
drugs that target various antigens on the tumors and tumor environment [34]. Antibodies may target surface 
antigens on tumor cells; for example, rituximab targets CD20 in non-Hodgkin B cell lymphoma, 
trastuzumab targets HER2 in breast cancer, and cetuximab targets EGFR in colorectal cancer [35] [36] [37]. 
These antibodies induce tumor cell death by blocking activation of growth and survival pathways, and 
engaging innate immune effector mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) 
[38].  
Some of the recent successes in antibody-based strategies stem from targeting the tumor environment and 
enhancing an antitumor immune response. One goal of these approaches is reversing tumor-mediated 
immunosuppression by targeting immunoregulatory co-receptors [39]. FDA-approved ipilimumab 
antagonizes the inhibitory receptor CTLA-4, expressed on activated T cells [40]. Several antibodies 
blocking the PD-1 and PD-1 ligand T-cell inhibitory signaling axis are in development and on the track for 
FDA approval [41]. Other approaches for enhancing T cell-specific immunity against tumors aim to activate 
stimulatory receptors, such as 4-1BB, OX40, CD27, CD40, and DR3 [42]. 
Cancer vaccines 
Cancer vaccines aim to induce tumor-specific T cells by introducing a tumor antigen together with an 
adjuvant. Ideally, therapeutic vaccines should eliminate tumors both by activating cytotoxic T cells and 
inducing a tumor-specific T cell memory that would prevent future tumor relapse [32]. Dendritic cells are 
one of the main candidates for vaccination vehicles, since their role is to bridge the innate and the adaptive 
immune response by stimulating T cells via antigen presentation [43]. Activated (mature) dendritic cells 
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are extremely efficient at antigen presentation and activating T cells compared to other antigen presenting 
cells and tumor cells [44]. Various approaches for exploiting dendritic cells for vaccination against cancer 
are explored in ongoing clinical trials [32]. One approach uses vaccines consisting of non-targeted peptide, 
protein or nucleic acid to be captured by patient’s dendritic cells, and these agents are frequently combined 
with granulocyte-macrophage colony-stimulating factor (GM-CSF) or various adjuvants such as toll-like 
receptor (TLR) agonists [45] [46]. A second approach is targeting the dendritic cells in vivo via coupling 
antigens to antibodies specific to surface receptors on dendritic cells [47]. Agents that are dendritic cell 
activators such as TLR3, TLR7-8, or CD40 agonists enable their maturation and activation [48]. Finally, a 
third approach is vaccination with ex vivo generated dendritic cells, which has been studied for many years 
and has recently resulted in FDA approval of the first therapeutic cancer vaccine Sipuleucel-T 
(PROVENGE by Dendreon) [1] [49]. Sipuleucel-T is approved for metastatic prostate cancer and it consists 
of enriched blood antigen presenting cells cultured with a fusion protein of prostatic acid phosphatase (PAP) 
and GM-CSF [50].  
Cytokines 
Cytokines are molecular messengers that can directly stimulate immune cells at the tumor site. They are 
secreted or membrane-bound proteins that are produced by cells of the innate and adaptive immune system 
in response to pathogens and tumor antigens [51]. Two cytokines were so far granted FDA approval as 
single agents for cancer treatment: IL2 for metastatic melanoma and renal cell carcinoma, and IFNα as an 
adjuvant therapy for stage III melanoma [52] [53]. Other cytokines have shown broad antitumor activity in 
preclinical models, and cytokines such as GM-CSF, IL7, IL12, IL15, IL18 and IL21 are being evaluated in 
clinical trials for patients with cancer [54] [55] [56] [57] [58]. Other efforts are focusing on neutralization 
of immunosuppressive cytokines, IL10 and TGFβ [59]. However, multiple roles of single cytokines in both 
immune activation and suppression, redundancy of cytokine signaling, and high potency of these agents 
makes it challenging to achieve high antitumor responses without causing toxicities. The full potential of 
cytokines likely lies in their use as components of combination therapy, together with small molecule 
inhibitors, vaccines, monoclonal antibodies or other agents that can reverse immunosuppression at the 
tumor site [60].   
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1.3 Adoptive cell therapy 
Adoptive cell therapy (ACT) involves the isolation and reinfusion of T cells with antitumor activity into 
cancer patients. Transferred cells can be either endogenous antitumor T cells or they can be genetically 
engineered to express receptors with antitumor activity [61]. Adoptive T cell therapy has shown remarkable 
effectiveness in clinical trials for certain cancers; for example 20-40% patients with metastatic melanoma 
can be cured using this approach, whereas the complete response rate for other treatments is 1-6% [62]. 
Objective response rates between 51% to 72% have been reported in heavily pretreated advanced melanoma 
patients [62]. 
Tumor infiltrating lymphocytes 
The first adoptive transfer cancer therapies were pioneered by Steven Rosenberg’s group at the National 
Cancer Institute (NCI) in Maryland. They were done with patients’ tumor infiltrating lymphocytes (TILs), 
grown from resected melanomas with the addition of IL2 [63]. These tumor-resident T cells can retain 
reactivity against endogenous tumor-associated antigens, and are effective in combination with a 
lymphodepleting preparative regimen and administration of IL2, with 22% of treated patients achieving a 
complete tumor regression [62]. Therapeutic success of TILs in melanoma is partially due to the high 
immunogenicity of these tumors, probably related to the fact that melanoma has the highest mutation rate 
of any cancer type [64]. Identifying T cells capable of recognizing cancer cells beyond melanoma without 
causing deleterious effects on normal cells is the major challenge for broad application of ACT [61].  
Genetically engineered T cells 
In order to empower T cells to recognize and eliminate cancers beyond melanoma, genetic engineering of 
patients’ lymphocytes using genes for antitumor receptors is under active research. Two types of receptors 
are currently developed for this purpose: variants of conventional T cell receptors (TCRs) and chimeric 
antigen receptors (CARs) [61]. TCRs are molecules naturally found on all T cells; they are heterodimers 
that are able to recognize peptides originating from intracellular proteins in the context of major 
histocompatibility complex (MHC) molecules on the cell surface [65] [66]. On the other hand, CARs do 
not occur naturally; they are chimeras between the antigen-recognizing portion of an antibody attached to 
intracellular T cell signaling domains such as CD3ζ, CD28 and 41BB. The introduction of CARs enables 
T cells to recognize an antigen the same way antibodies do - without MHC restriction and with capability 
of recognizing a wider variety of structures [67]. Genes for TCRs and CARs with favorable antitumor 
activity can be inserted into retroviruses or lentiviruses which can transform lymphocytes from patients and 
convert them into cells capable of killing tumors [68].  
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Differentiation state and activity of tumor specific T cells 
Emerging findings from both preclinical studies and clinical trials highlight the importance of the 
differentiation state of the adoptively transferred T cell populations to the success of ACT [69]. Upon their 
activation, T cells begin to proliferate and differentiate, and they need to be fully differentiated for optimal 
antitumor efficacy [70]. However, it is evident that T cell differentiation is inversely correlated with 
persistence and antitumor efficacy of transferred cells. For CD8+ T cells, T memory stem (TSCM) cells are 
more effective against tumors than central memory T (TCM) cells, which are more effective than effector 
memory T (TEM) cells [71]. Recently, CD8+ T memory stem (TSCM) cells are emerging as a favorable 
developmental stage for ACT, since they proliferate extensively and they can further differentiate into TCM 
and TEM cells [72]. 
A lymphodepleting regimen that removes immunosuppressive cellular elements within the tumor 
microenvironment before ACT results in higher levels of durable responses in patients [73]. 
Lymphodepletion is a temporary ablation of the immune system in a patient with cancer, accomplished 
using chemotherapy alone or in combination with total-body irradiation [69]. Several mechanisms might 
contribute to the enhanced efficacy of transferred T cells in the lymphodepleted host environment. These 
mechanisms include elimination or reprogramming of myeloid derived suppressor cells (MDSCs) [74], 
elimination of suppressive regulatory T cells (Tregs) [75], depletion of endogenous lymphocytes that 
compete for homeostatic cytokines [76], and increased functionality of APCs, partly mediated by bacterial 
translocation across intestinal epithelium accompanying total-body irradiation [77]. 
Choosing the right targets for ACT 
The identification of appropriate tumor antigens is perhaps the greatest challenge now facing the field of 
cancer immunotherapy [78]. Potentially targetable tumor-associated antigens that T cells can recognize fall 
into five major categories [69]: 
First, unaltered tissue-differentiation antigens shared between the tumor and the non-malignant cells that 
the tumor originated from can be used as a target, as long as the antigen is present on tissues non-essential 
for life. The biggest success of ACT with engineered T cells has been seen with targeting an antigen from 
this category, CD19. CD19 is expressed on B cell lymphomas, as well as on normal B cells [79]. Other 
antigens in this category include carcinoembryonic antigen (CEA) (present on colon cancer and normal 
colon) [66] and melanocyte differentiation antigens (MDAs) — such as PMEL (also known as gp100), 
melanoma antigen recognized by T cells 1 (MART1), tyrosinase, tyrosinase-related protein 1 (TYRP1) and 
TYRP2 (on most melanoma tumors but also on normal melanocytes) [80].  
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In the second category of targetable antigens are products of mutated genes, since T cells potentially 
recognizing these neo-antigens were not subject to central tolerance. High incidence of mutations is 
particularly characteristic for melanoma [81]. The third category includes viral antigens, for cancers 
associated with virus infections, such as those derived from Epstein–Barr virus and human papillomavirus 
(HPV) [82] [83]. The fourth category includes antigens produced by epigenetic changes, most notably 
cancer-testis antigens that are products of genes inactive in normal non-germline tissues. Examples include 
NY-ESO-1, MAGEA3 and synovial sarcoma X breakpoint 2 (SSX2) [84] [85]. Finally, the fifth category 
includes targetable antigens on non-transformed tumor vasculature and stroma that support tumor 
sustenance; examples include fibroblast activation protein (FAP) and vascular endothelial growth factor 
receptor 2 (VEGFR2), expressed at higher levels at tumor neo-vasculature [86] [87].  
ACT clinical trials: successes and challenges  
Recent clinical trials have revealed successes as well as drawbacks of targeting previously discussed tumor-
associated antigens. CD19 is an almost ideal target for cancer therapy – apart from cancer cells, it is present 
only on B cells in the body, which are necessary for normal life but not essential for patient’s survival [88]. 
The success of anti-CD19 CAR therapy is one of the reasons for the 2013 Science Magazine designation 
of breakthrough of the year for cancer immunotherapy [3]. Some of the successful recoveries were the topic 
of national news, like the story of the first pediatric patient with acute lymphoid leukemia (ALL) to be 
treated with genetically modified T cells at the University of Pennsylvania by the team of Dr. Carl June 
[89] [90]. Unfortunately, this type of target is very difficult to find in other types of cancers, and treating 
solid tumors presents with an additional share of challenges. 
A recent clinical milestone from Dr. Rosenberg’s group was a tumor regression in a patient with metastatic 
epithelial cancer treated with TILs enriched for T cells recognizing a mutation in their own cancer, 
identified by a whole-exomic-sequencing-based approach [91]. This is the first reported instance of T cell 
therapy tailored to specific mutations in patient’s cancer; however, the reported results are from a single 
patient study, so conclusions should be cautiously extrapolated. 
Clinical trials have shown undesirable, sometimes even detrimental autoimmune effects of targeting certain 
tumor-associated antigens initially considered favorable. T cells targeting MART1 caused toxicity to 
melanocytes in the skin, eye and ears in almost all treated patients, and had limited antitumor efficacy [65]. 
Similarly, T cells targeting carcinoembryonic antigen (CEA) resulted in partial response in one of three 
patients with metastatic colorectal cancer; however dose-limiting diarrhea due to autoimmune colitis 
developed in all treated patients [66]. Some of the adverse effects of ACT with engineered T cells resulted 
from unanticipated cross-reactivity of the TCRs with unintended antigens (“off tumor, off target” toxicity). 
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Notably, a TCR specific for an epitope from the cancer-testis antigen MAGEA3 caused severe neurological 
toxicities in patients, because the TCR unexpectedly recognized a nonidentical epitope of a brain protein, 
MAGEA12 [92]. Another trial targeting MAGEA3 with a different TCR reported fatal cardiac toxicity, 
shown to be due to the cross reactivity of engineered T cells with a normal myocardial protein titin [93].  
A lot of these targets were previously targeted by cancer vaccines, without significant autoimmunity. This 
highlights the potency of the ACT approach, and also a need for careful evaluation of TCR and CAR cross-
reactivity with self-antigens and determining the clinical relevance of even very low levels of target 
expression in normal tissues [94]. 
Concluding remarks on ACT 
Despite cautious optimism prevalent in cancer immunotherapy circles, there is still a long way to go before 
ACT for cancer becomes safe and available on a larger scale. Like any personalized therapy, the logistics 
and cost of having to propagate and manipulate individuals’ cells might be a prohibitive factor in the 
application of this therapeutic modality [95]. However, with recent involvement of the big pharmaceutical 
companies like Novartis in the development of the infrastructure required for the widespread availability 
of this technology and a high likelihood of TCRs and CARs being available “off the shelf”, some challenges 
of this kind might be circumvented in the foreseeable future [68]. Efficacy of ACT may also be augmented 
with combination therapies, such as therapeutic vaccination, checkpoint inhibition, agonistic antibodies, 
small molecule inhibitors of tumors, and targeting of tumor stroma and neo-vasculature. Finding the optimal 
targets and the right regimen for successful T cell therapy remains the main challenge to broad anticancer 
application of ACT. 
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1.4 Oncolytic virotherapy 
Oncolytic virotherapy is emerging as a promising antitumor strategy that has immunological dimensions. 
The safety of several virus platforms has been confirmed in early-stage clinical trials, and viruses from 
three families (herpes-, pox- and adenoviruses) are currently being evaluated in advanced clinical trials 
[96]. New genetic engineering strategies have led to improved systemic administration, better tumor 
specificity and improved antitumor efficacy [97]. 
Oncolytic viruses are therapeutically useful viruses that can selectively infect and destroy cancerous tissues 
without causing harm to normal tissues [98]. Cancer cells are in general more susceptible to viruses than 
their nontransformed cellular counterparts, since during the malignant transformation they often lose the 
potent innate antiviral response pathways, including type I and II interferon (IFN) and tumor necrosis factor 
(TNF) responses [99]. Viruses have evolved specificities for different cell types, and this natural diversity 
is useful for developing therapies for different tumors; hence, multiple viral families (currently nine) are 
being evaluated in clinical trials [100]. 
Specific tropism of an oncolytic virus to the cancer cell is an essential requirement for successful cancer 
therapy. Certain viruses exhibit an inherent preference for malignant cells, and others are engineered for 
improved oncotropism [99]. The first generation of engineered viruses had their virulence factors deleted 
to attenuate replication in normal cells; however this reduced their replication and effectiveness in cancer 
cells as well. The next generation of engineered viruses focused on methods of enhancing specificity of the 
viruses to cancer cells with improving their antitumor potency [97].  
Based on the results from current clinical and preclinical trials, it is no longer regarded as essential for the 
therapeutic virus to directly infect and kill every cancer cell in the patient. It is becoming evident that 
antitumor immune responses induced by viral therapy are key determinants of therapy success [101]. 
Oncolytic viruses can cooperate with host immune system in a number of ways; viruses can be delivery 
vehicles for death signals specific for cancer cells, they can be used as gene therapy vectors for expression 
of anticancer genes, or they can upregulate antitumor immunity via their oncotropic immunostimulatory 
properties [102]. 
Brief history of oncolytic virotherapy 
The history of using pathogens as antitumor reagents starts with history of immunotherapy and Dr. Coley’s 
experiments, as addressed above. A number of early clinical trials conducted in 1950s and 1960s used 
impure oncolytic virus preparations, including body fluids containing human or animal viruses; they 
generally failed to impact tumor growth, and had high morbidity rate [103]. Despite occasional successes, 
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such as tumor regressions in 37 out of 90 terminal cancer patients treated with mumps virus at Osaka 
University, this work was not pursued beyond the 1970s [104]. The re-emergence of oncoviral therapeutic 
strategies came with the advent of genetic engineering and the ability to improve tumor-specificity and 
other aspects of viral antitumor properties [105]. Since a landmark study in which a thymidine kinase–
negative Herpes Simplex Virus (HSV) with attenuated neurovirulence was shown to be active in a murine 
glioblastoma was published in 1991 [106], dozens of different viruses have been engineered for cancer 
therapy.  
Overview of current clinical trials 
The oncolytic virus that has had most notable success in clinical trials so far is a modified herpesvirus, 
Talimogene laherparepvec (T-VEC, formerly OncoVex, developed by Amgen). T-VEC is an oncolytic 
HSV genetically manipulated to drive the expression of human granulocyte macrophage–colony 
stimulating factor (GM-CSF) by infected cells [107]. In the phase II clinical trial, this virus was 
administered by direct intratumoral injection to patients with metastatic malignant melanoma and led to 
complete regression of lesions in 8 of 50 treated patients [108]. Tumor shrinkage was noted in injected as 
well as non-injected lesions, demonstrating that systemic immunity was induced [109]. It was recently 
announced that the phase III trial, in which T-VEC effect was compared to GM-CSF alone, has met its 
primary endpoint of durable response rate (complete or partial response lasting for at least six months); the 
T-VEC group had 10.8% complete responders in comparison to 0.7% complete response rate in the GM-
CSF alone group [102]. These results suggest that T-VEC might be close to FDA approval for use in 
melanoma patients [96].  
Another notable example of an oncolytic virus in the late stage of clinical testing is a poxvirus JX954 
(developed by Transgene as Pexa-Vec), an oncolytic vaccinia virus also engineered to express GM-CSF 
[110]. In the completed phase II clinical trial, JX594 was shown to induce objective responses in 15% of 
hepatocellular carcinoma patients [111]. Eight current clinical trials are assessing the safety and antitumor 
profile of JX594 for hepatocellular carcinoma and other cancers [96]. 
In addition to these two notable examples, there have been published clinical studies using a variety of other 
viruses, including attenuated adenoviral strains, Newcastle disease virus for glioma and other solid tumors, 
parvovirus for glioblastoma, and reovirus for glioma, melanoma and other solid tumors. The majority of 
these studies were phase I/II trials, most often reporting favorable safety data and sporadic antitumor 
activity. Currently, there are 52 ongoing clinical trials assessing the safety and antitumor potential of 
oncolytic viruses from ten different viral families in cancer patients [96]. 
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Improving viral antitumor potential 
Despite the promising results, oncolytic viruses that have been used in advanced clinical trials have not met 
efficacy milestones expected from preclinical models. Based on lessons learned, current preclinical studies 
are focusing on resisting virus neutralization, improving tumor specificity, arming the virus for improved 
antitumor activity, and exploring different combination therapies [97]. Our own preclinical work has 
employed an oncolytic virus, myxoma virus, to deliver a cytokine gene to engender the local secretion 
within the tumor of a potent cytokine that activates cytotoxic T cells and natural killer cells.  
Resisting neutralization 
Intravenous administration of oncolytic viruses is the preferred administration route for the treatment of 
metastatic disease; however systemic delivery makes the virus susceptible to neutralization by pre-existing 
antibodies in the blood and by the mononuclear phagocytic system (MPS) of liver and spleen [96]. Genetic 
engineering strategies are developed for shielding the viruses by changing or physically masking the 
epitopes recognized by antibodies. Modifications have been made so far for vesicular stomatitis virus 
(VSV), adenovirus and measles virus [112] [113]. Altering the antibody recognition epitopes in oncolytic 
viruses as well as regimen of combination therapy with pharmacological immunosuppression should help 
in effectively initiating viral antitumor action [99].  
Tumor selectivity 
Virus selectivity for cancer cells can be enhanced either on the virus entry level (virus recognizing surface 
proteins) or post-entry on the virus replication level [97]. Entry targeting is improved by fusion or 
conjugation of specificity domains with virus entry receptors, for example retargeting HSV to breast cancer 
cells by engineering its glycoprotein D to express single-chain antibody for HER2 [114]. Tumor-replication 
targeting takes advantage of altered gene expression in cancer cells and it involves using promoters and 
engineered microRNA target sequences. For example, herpesviruses have been engineered to express wild-
type virulence factors under hepatocellular carcinoma-specific promoters [115], and a number of viruses 
have been modified to express miRNA target sequences that will stop their replication in normal cells 
(certain miRNAs have abnormally low expression in tumor cells) [116]. These novel approaches minimize 
off-target toxicities while preserving potent virus replication in cancer cells [117]. 
Arming the virus 
Ability to access all cells within a tumor remains a clinical challenge even for viruses that can specifically 
and effectively infect the tumor. A desirable consequence of productive virus infection would be induction 
of “bystander cell killing”, where the virus would cause destruction of surrounding cells that are not directly 
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infected [97]. Different strategies have been employed to arm the viruses to induce this remote destruction. 
First, viruses armed with prodrug convertases can be used to activate prodrugs used for chemotherapy, as 
in the combination of adenovirus with the purine nucleoside phosphorylase (PNP) transgene with prodrug 
fludarabine [118], used in a current clinical trial. Second, viruses that express ion transport proteins can 
increase radiation poisoning when combined with radioisotopes, such as measles virus expressing human 
sodium–iodide symporter (NIS) in combination with radioactive iodine [119]. Third, viruses are engineered 
to express immunostimulatory factors can induce innate and adaptive immune responses to tumor-
associated antigens, most famously so far with viruses expressing GM-CSF to stimulate the production of 
granulocytes and monocytes, which in turn stimulate adaptive immunity [120] [121]. 
Combination therapies 
Immune checkpoint blockade strategies, such as blocking immune inhibitory molecules CTLA-4, PD-1, 
PD-L1, are currently being explored as combinatorial therapeutics with oncolytic viruses [122]. For 
example, T-VAC is being tested in combination with the anti-CTLA-4 antibody ipilimumab [96]. In 
addition to combinations with viruses engineered to express prodrug activating enzymes, a number of 
chemotherapeutic drugs in use are potentially synergistic with oncolytic viruses [123]. For example, the 
nucleoside analog gemcitabine increases the efficacy of certain viruses [124].  
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1.5 Oncolytic myxoma virus for gene delivery 
Another way that an oncolytic virus can be combined with other approaches is to use the virus to selectively 
deliver a gene to cancer cells in order to have a protein expressed only in the tumor. For example, virally 
delivered genes for cytokines could promote the responses of immune cells within the tumor environment 
and avoid systemic toxicity from inflammatory actions of the cytokine. We have explored the use of the 
oncolytic myxoma virus for this purpose. 
Myxoma virus is a poxvirus that infects only rabbits and European Brown Hares in the wild, and is 
nonpathogenic in all other animals tested [125]. It causes lethal disease called myxomatosis in the European 
rabbit and it was used in the 1950’s in an attempt to control the Australian feral rabbit population [126]. 
Despite its lack of broad pathogenicity, myxoma virus can replicate in cultured cells from many species, 
including most human cancer cells which are particularly permissive for the virus [127] [128] [129]. 
Myxoma has several advantages over other oncolytic viruses: humans have no prior immune response 
against it; it is completely safe in humans and mice; it replicates in the cytoplasm and does not integrate 
into genomic DNA [130]. Its large linear double stranded DNA genome consisting of 159 unique viral 
genes allows for as much as 25kb of contiguous DNA to be inserted, therefore enabling the expression of 
potential therapeutic and reporter genes [125] [127]. 
Antitumor properties of myxoma virus were shown in a number of preclinical studies since the first reports 
of its oncolytic activity. Lun et al. first demonstrated oncolytic activity of myxoma virus in vivo in 2005; 
they showed that myxoma virus cured human glioma xenografts in 92% virus-treated nude mice [131]. 
Activity in human xenograft model in nude mice was also showed for rhabdoid tumors [132]. Human 
medulloblastoma xenograft mouse models showed prolonged survival upon treatment with myxoma virus, 
and animal survival was further enhanced with the combination treatment with rapamycin, an mTOR 
inhibitor [133]. Oncolytic potency of myxoma virus in syngeneic tumor models was shown by Stanford et 
al.: virus treatment caused growth inhibition of primary B16-F10 melanoma tumor, as well as reduced 
number of lung tumor burden in the metastatic model [134].  
Binding and entry by poxviruses into mammalian cells is generally not restricted at the cell surface level, 
contrary to some other oncolytic viruses. The mechanism of specificity and cell entry, even for the well-
characterized poxviruses such as vaccinia virus, was unknown until recently. It is now known that vaccinia 
induces cellular uptake via endocytosis triggered by exposed phosphatidylserine residues on the viral 
membrane, mimicking absorption of apoptotic cells [135]. It has been shown recently that vaccinia and 
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myxoma exploit different mechanisms to enter and infect human cancer cells, which provides some 
rationale for their divergent cancer cell tropisms [136].  
Non-permissive cells can abort the replication cycle of the virus, while signaling defects in cancer cells 
permit productive viral replication. Tropism of myxoma virus to human cancer cells is linked to 
hyperactivation of serine/threonine kinase Akt in these cells [129]. A viral host range protein M-T5 has 
been shown to regulate the ability of myxoma virus to propagate in human tumor cells [137]. M-T5 forms 
complexes with two human intracellular proteins: Cullin-1 and Akt-1. The interaction of M-T5 with Cullin-
1, an E3 ubiquitin ligase involved in cell cycling, prevents cell cycle arrest and apoptosis to allow viral 
replication. Binding to M-T5 activates Akt, an important serine/threonine kinase involved in survival, 
proliferation and cell death. Permissiveness of myxoma infection is directly dependent on level of 
phosphorylation (activation) of Akt. Many human cancers exhibit hyperactivated Akt. The molecular 
mechanism of Akt/MT-5 interaction is under active investigation [130]. 
Rapamycin, an immunosuppressant with antitumor effects, has the ability to increase the oncolytic potential 
of myxoma virus [133]. Rapamycin acts directly on the mammalian target of rapamycin (mTOR1) and has 
the ability to increase viral replication that correlates with Akt activation. [138] [139]. Treatment of semi-
permissible, but not fully permissible or non-permissible, human cancer cells with rapamycin increases 
viral replication and spread in vitro [138]. These results suggest that pre-treatment with this drug may be 
necessary for productive tumor infection by myxoma virus in vivo [134] [140]. Furthermore, results from 
our laboratory show that rapamycin treatment did not impair T cell-mediated tumor destruction, supporting 
the feasibility of combining adoptive immunotherapy and rapamycin-enhanced virotherapy [141].  
Interleukin 15 (IL15) and IL15Rα 
Discovery and characterization of cytokine IL2 provided an important stimulus to the development of 
cancer immunotherapy [61]. Clinical trials conducted from the 1980’s to present day showed the ability of 
high-dose IL2 to mediate durable complete regressions, and it was approved by the FDA for the treatment 
of patients with metastatic renal cancer in 1992 and metastatic melanoma in 1998 [61]. Today, other 
recombinant cytokines and hematopoietic growth factors are also approved for use as supportive agents in 
cancer, notably interferon-α (IFNα) for the surgical adjuvant treatment of high-risk malignant melanoma 
[142]. 
Interleukin 15 (IL15) was at the top of the National Cancer Institute's list of agents with the greatest potential 
use in tumor immunotherapy in 2007 [143], and currently five cancer clinical trials using IL15 are ongoing 
or recently completed [144]. Notably, one of the clinical trials uses recombinant human IL15 as a 
monotherapy for refractory metastatic melanoma and metastatic renal cell cancer and another trial is 
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evaluating use of IL15 after chemotherapy combined with the administration of patient-derived tumor-
infiltrating lymphocytes (TIL) in metastatic melanoma [145]. None of the clinical trials yet employ 
IL15/IL15Rα complexes (discussed below). 
IL15 activates important mechanisms of antitumor immunity, including development and activity of both 
NK cells and CD8+ T cells and promoting development of memory T cells [146]. These functions overlap 
with the functions of IL2, with whom IL15 shares the IL2R/IL15Rβ and common gamma (γc) chain receptor 
subunits [145]. However, in many cancer relevant adaptive immune responses, IL2 and IL15 have distinct 
roles. Unlike IL2, IL15 does not induce regulatory T cell activity (Tregs) which attenuate immune response 
to cancer [147]. IL15, in contrast to IL2, inhibits activation-induced cell death (AICD) of CD8+ effector T 
cells [148]. Application of high doses of IL2 is accompanied by severe toxicity [149], while preclinical 
studies have shown little vascular capillary leak with IL15 in contrast to IL2 [150]. 
IL15 belongs to the family of the common gamma chain (γc) or four-helix-bundle cytokines, which includes 
IL2, IL4, IL7, IL9, IL15, and IL21. Receptors for these cytokines share the common γc chain (CD132) and 
have unique α chains [146]. IL2R and IL15R have additional identical IL2/15Rβ chains (CD122), as 
mentioned previously. Although IL15 mRNA expression is widespread, IL15 protein is largely detectable 
only in monocytes/macrophages and dendritic cells. IL15 expression is tightly regulated at the post-
transcriptional level, probably because of its potency as an inflammatory cytokine [145].  
The unique α subunit of the IL15 receptor complex (IL15Rα) binds to IL15 with high affinity (Kd less than 
10–11 M) and retains IL15 on the cell surface. In the physiological setting, IL15 is trans-presented by IL15Rα 
to the IL2/15Rβ-γc receptor component on nearby effector NK and T cells [151] [152]. IL15 can persist in 
this membrane-bound form for many days via endosomal recycling and this mechanism probably limits 
exposure of target cells to circulating IL15 [145]. IL15 signaling in lymphocytes activates the JAK1/JAK3 
and STAT3/STAT5 pathways, Syk kinase and phospholipase C (PLC)γ, Lck kinase, and Shc resulting in 
the activation of PI3K/Akt and Ras/Raf/MAPK signaling cascades. These pathways lead to the subsequent 
expression of Bcl2, Myc and Fos/Jun and NF-κB activation [153]. 
Many approaches have been employed in an effort to increase the antitumor effects of IL15. Since IL15Rα 
may be considered a part of the active IL15 cytokine complex rather than part of the receptor, some of the 
improving approaches include pre-association of IL15 with IL15Rα [146]. Mutual stabilization of IL15 and 
IL15Rα leads to increases in production, stability, and tissue availability of bioactive IL15 in vivo [154]. 
Soluble IL15/IL15Rα complexes greatly enhanced IL15 half-life and bioavailability in vivo and 
dramatically reduced tumor burden in a model of B16-F10 melanoma [155] [156]. IL15 preassociated with 
a chimeric protein of the extracellular domain of murine IL15Rα and the Fc portion of human IgG1 also 
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increased antitumor activity against melanoma [157]. Importantly, this effect is preserved when the 
cytokine and the α receptor subunit are covalently joined and expressed as a single protein. Fusion protein 
of the N-terminal domain of IL15Rα and IL15 reduced tumor burden in the mouse B16F10 melanoma 
model and in an orthotopic human colon carcinoma model [158]. In Kranz laboratory the strategies of single 
chain TCR-mediated targeting of the IL15-IL15Rα fusion protein are currently explored [159]. These 
results hold significant importance for the use of IL15/IL15Rα complexes as a potential adjuvant or 
therapeutic. 
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CHAPTER TWO 
MYXOMA VIRUS EXPRESSING A FUSION PROTEIN OF INTERLEUKIN-15 (IL15) 
AND IL15 RECEPTOR ALPHA HAS ENHANCED ANTITUMOR ACTIVITY 
2.1 Introduction 
The oncolytic potential of many viruses, such as the poxviruses vaccinia virus and myxoma virus, initially 
suggested that they could be used as cancer therapy, but the efficacy of such viruses as a single agent in 
vivo has been limited [1]. Alternatively, the selectivity of such oncolytic and oncotropic viruses can be used 
to deliver cytokine genes to cancer cells [2][3]. One goal of this approach is to shift the immunosuppressive 
microenvironment found in many solid tumors to an environment that better favors the induction of 
antitumor immune responses. 
Myxoma virus is an oncotropic poxvirus that has a particularly attractive safety profile. In the wild, the 
virus infects only rabbits and other related leporids, and is nonpathogenic in all other nonlagomorph animals 
tested [4]. Despite its lack of broad pathogenicity other than the rabbit, myxoma virus can replicate in 
diverse cultured cells from many species, including most human cancer cells, which are particularly 
permissive for the virus [5][6][7]. It also selectively infects tumors in human xenograft models 
[8][9][10][11] and primary mouse tumors [11][12][13]. It has recently been shown that myxoma virus can 
discriminate cancerous human myeloid cells from normal CD34+ stem cells, which makes it a potential ex 
vivo purging agent for hematological malignancies [14][15]. 
Some oncotropic viruses tested in clinical trials have been modified to express an immunostimulatory 
cytokine, GM-CSF [16][17]. Although GM-CSF is a cytokine with potentially favorable antitumor activity, 
it can also stimulate suppressive components of the immune system [18]. Therefore, it is worth exploring 
other cytokine candidates to be delivered by a tumor-selective viral vector, particularly those that are known 
to be capable of activating non-responsive or anergic cytotoxic lymphocytes [19].  
IL15 is a pro-inflammatory cytokine with significant potential for stimulating T lymphocytes and NK cells 
against cancer [20]. IL15 expression is tightly regulated at the post-transcriptional level, making IL15 
protein largely detectable only in monocytes/macrophages and dendritic cells [21]. Co-expression of IL15 
with the α subunit of IL15 receptor (IL15Rα) greatly enhances IL15 stability and function in vivo 
[22][23][24]. Since IL-15Rα may be considered a part of the active IL-15 cytokine complex rather than part 
of the receptor, pre-association of IL-15 with IL-15Rα generates a more potent ligand compared to the 
cytokine alone [25][26][27][28]. Recombinant myxoma viruses have previously been engineered to express 
tdTomato red fluorescent protein (vMyx-tdTr) and mouse interleukin-15 (vMyx-IL15-tdTr) [29]. Our 
previous studies have shown that these myxoma viruses (vMyx-tdTr and vMyx-IL15-tdTr) productively 
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infect cancer cells in vitro, but have limited effect on tumor progression of murine melanoma in immune 
competent mice in vivo [30][31]. In order to deliver the biologically potent form of IL15 with its IL15R 
component in vivo, we engineered a new recombinant myxoma virus (vMyx-IL15Rα-tdTr), which 
expresses IL15Rα-IL15 fusion protein, as well as tdTomato red fluorescent reporter protein.  
In this study, we describe the therapeutic effects observed with the new recombinant virus in a mouse model 
of aggressive melanoma, B16-F10. In vitro testing of the virus showed that B16-F10 cells are permissive 
to the vMyx-IL15Rα-tdTr infection. Secretion of the IL15Rα-IL15 fusion protein was confirmed by ELISA 
and functional activity of the fusion was assessed by a proliferation assay on IL15-dependent CTLL-2 cells. 
In in vivo experiments, immunohistological analysis of the subcutaneous tumors showed dramatically 
increased infiltration of NK cells in vMyx-IL15Rα-tdTr treated tumors compared to controls in RAG1-/- 
mice. In immunocompetent C57BL/6 mice, vMyx-IL15Rα-tdTr increased infiltration by NK cells and 
CD8+ T cells. RAG1-/- mice with subcutaneous B16-F10 tumors were treated with vMyx-IL15Rα-tdTr, 
resulting in a significant survival benefit for the treated group compared to the PBS control and the control 
viruses (vMyx-IL15-tdTr that expresses the native IL15 ligand and control vMyx-tdTr). Treatment of 
tumor-bearing C57BL/6 mice with vMyx-IL15Rα-tdTr resulted in longer survival than similarly treated 
RAG1-/- mice. Our results suggest that virally delivered IL15Rα-IL15 drives the recruitment of NK cells 
and T cells to the site of the tumor and that both the innate and adaptive components of the host immune 
system play a role in the antitumor effect.   
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2.2 Materials and methods 
DNA constructs 
pBluescript SK+ plasmid that served as a cloning backbone for the IL15Rα-IL15 – tdTomato expression 
cassette was obtained from ATCC (Manassas, VA). Whole viral DNA isolated from vMyx-tdTr [29] using 
the DNeasy Tissue Kit (Qiagen, Valencia, CA) was used as a template for obtaining the PCR fragment 
containing partial sequences of M135 and M136 genes. HindIII and BamHI cutting sites were introduced 
in this PCR reaction; primers for all PCR reactions were obtained from Integrated DNA Technologies 
(Coralville, IA) (Forward primer: 5'- CCA AAG CTT CAC CTG TGT ATG TT -3', Reverse primer: 5'- 
CCA GGA TCC ATA ACA CAC AGT TCG G -3'). PCR product from vMyx-tdTr was ligated into 
pBluescript using the T4 Ligase (Invitrogen, Carlsbad, CA) following sequential digestion with HindIII and 
BamHI (New England BioLabs, Ipswich, MA). IL15Rα-IL15 fusion protein contains codon-optimized 
sequence for the murine IL-15Rα sushi domain (amino acids 34-103 of Isoform 1, UniProt accession 
#Q60819), a linker with the sequence GG(SGG)6 and murine IL-15; it was purchased from GenScript 
(Piscataway, NJ) [32]. Poxvirus vvSynE/L promoter, murine Ig κ-chain leader sequence (which directs the 
protein to the secretory pathway) as well as BspEI and NdeI cutting sites were added and His tag was 
eliminated from the original IL15Rα-IL15 sequence using forward primer: 5'- CGC AGC TCC GGA AAA 
AAT TGA AAT TTT ATT TTT TTT TTT TGG AAT ATA AAT AAG ATG GAG ACA GAC ACA CTC 
CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACT GGT GAC ACC ACC TGC CCC 
CCC CCC GTG -3' and reverse primer: 5'- TCG CGC CAT ATG TTA TCA GCT GGT GTT GAT GAA 
CAT CTG CAC G -3'. The resulting IL15Rα-IL15 sequence was cloned into the earlier described 
pBluescipt construct using BspEI and NdeI (New England BioLabs, Ipswich, MA) and T4 Ligase 
(Invitrogen, Carlsbad, CA). Finally, tdTomato was cloned out of the plasmid provided by Dr. Brian 
Freeman (University of Illinois) using primers: forward 5'- GCA GTC GAC ATG GTG AGC AAG G – 3’ 
and reverse: 5’- CCT GAA TTC TTA CTT GTA CAG CTC G – 3’ and cloned into the existing pBluescript 
construct using SalI and EcoRI. Resulting plasmid, pBS-IL15Rα-IL15-tdTomatoRed (Figure 2.1) was used 
for creating vMyx-IL15Rα-tdTr. 
Recombinant viruses 
The Lausanne strain of myxoma virus (vMyx-Lau) was used to create recombinant virus expressing tandem 
dimer Tomato red fluorescent protein (vMyx-tdTr) with or without expression of interleukin-15 (vMyx-
IL15-tdTr) by intergenic insertion of the gene cassettes between M135R and M136R of the myxoma virus 
genome as previously described [29]. Protein expression of IL15 by this recombinant virus is driven by a 
vaccinia virus late promoter (p11).  
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The recombinant virus expressing the IL15Rα-IL15 fusion protein (vMyx-IL15Rα-tdTr) was created by 
homologous recombination in RK-13 cells infected with wild type (WT) vMyx-Lau followed by 
transfection with the engineered recombination vector pBS-IL15Rα-IL15-tdTomatoRed (Figure 2.1). The 
recombination vector contains genes for the IL15Rα-IL15 fusion protein and tdTomato, both under control 
of the same synthetic vaccinia virus early/late promoter (vvSynE/L promoter). This expression cassette is 
flanked by M135 and M136 partial gene sequences for the purpose of being transfected into the WT 
myxoma virus genome between genes M135 and M136. Myxoma virus permissive RK-13 cells were 
infected with WT vMyx-Lau followed by cationic lipid transfection of the engineered recombination vector 
pBS with the IL15Rα-IL15-tdTr cassette. After plasmid recombination into the virus, recombinant virus 
expressing IL15Rα fusion protein was propagated and titrated by focus formation on RK-13 cells. 
Fluorescent virus foci were harvested, repropagated and titrated on RK-13 cells. This process was repeated 
three times to isolate a purified virus which contains two exogenous genes; IL-15Rα-IL15 fusion protein 
and tdTomato. Genomic structure of recombinant virus was confirmed by PCR sequencing.  
Cell culture and reagents 
Rabbit kidney epithelial (RK-13) cells were a gift from Dr. Richard Moyer (University of Florida, 
Gainesville, FL; originally from ATCC, Manassas, VA). RK-13 are grown at 37°C, 5% CO2, and 100% 
humidity in minimum essential medium with Earle’s salts (Mediatech, Manassas, VA) supplemented with 
2 mM glutamine, 50 U/mL penicillin G, 50 µg/mL streptomycin, 1 mM sodium pyruvate, 0.1 mM 
nonessential amino acids (MEM-C), and 10% fetal bovine serum (FBS; HyClone, Logan, UT).  
The murine melanoma cell line, B16-F10 was purchased from ATCC (Manassas, VA). The murine glioma 
cell line GL261 was obtained from the National Cancer Institute-Frederick Cancer Research Tumor 
Repository (Frederick, MD). B16.SIY was derived from B16-F10 cells retrovirally transduced to express 
green fluorescent protein (GFP) as a fusion protein with SIYRYYGL (SIY) [33,34] and was a gift from Dr. 
Thomas Gajewski (University of Chicago, Chicago, IL).  
Cancer cell lines were cultured in complete Roswell Park Memorial Institute (RPMI) 1640 medium 
containing 5 mM HEPES, 1.3 mM L-glutamine, 50 µM 2-ME, penicillin, streptomycin and 10% fetal 
bovine serum (FBS) at 37°C and 5% CO2. 
Cytotoxic T Lymphocyte Line 2 (CTLL-2) cytokine-dependent murine T cell line (ATCC, Manassas, VA) 
was cultured in complete RPMI 1640 medium additionally supplemented with 10% T-Stim (culture 
supernatant from rat T cells stimulated with ConA from BD Biosciences, San Jose, CA). 
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Viral growth curves 
Tested cell lines were plated into 6-well cell culture plates (Nunc, Roskilde, Denmark) and grown in MEM-
C with 10% FBS until they reached 90-95% confluency. For multi-step growth curves cells were inoculated 
with vMyx-IL15Rα-tdTr or vMyx-tdTr diluted in 400µL MEM-C at a multiplicity of infection (MOI) of 
0.1 plaque-forming units (PFU) per cell. Inoculated cells were incubated at 37°C and 5% CO2 for 1h, 
rocking every 15 min. Next, virus was removed, cell monolayers were washed with phosphate-buffered 
saline (PBS), and MEM-C with 10% FBS was added to each well. Inoculations of each cell line were 
performed in triplicate. At 0, 4, 8, 12, 24 and 48 h post-inoculation, cells were dislodged by scraping into 
media. Cells were collected by centrifugation at 500xg for 5 min. Next, each supernatant was removed, and 
the cellular pellet was resuspended in 0.5 ml PBS and stored at -80°C. Prior to titering the virus, cells were 
disrupted by three freeze/thaw cycles and sonication in order to release the virus from the cells. Samples 
were titered in duplicate. Titering was performed by plating 10-fold serial dilutions of the samples in MEM-
C onto RK-13 monolayers in 6-well or 24-well culture plates. The inoculated cells were incubated for 1h 
at 37°C and 5% CO2, then the inoculum was removed and an overlay consisting of equal amounts of 1% 
agarose (Lonza, Rockland, ME) and 2×MEM-C with 20% FBS was added on RK-13 cells. Viral plaques 
were visualized as small white foci (red foci under fluorescent light) and counted at 6-7 days post-
inoculation (dpi). 
ELISA analysis of the IL15Rα-IL15 fusion protein 
RK-13 cells were plated in 6-well culture plates and upon reaching 90-95% confluency they were inoculated 
with vMyx-IL15Rα-tdTr or vMyx-tdTr diluted in 400µL MEM-C at MOI of 5 PFU/cell. After 1h 
incubation at 37°C and 5% CO2, inoculum was replaced with MEM-C with 10% FBS. At different time 
points post-inoculation, both cell supernatant and cellular extract were collected. Supernatants were 
centrifuged briefly to remove cellular debris and clarified supernatants were transferred to new tubes and 
stored at -80C. The remaining cellular monolayer was detached from the well by scraping cells into 1 ml 
PBS. Cells were collected, pelleted by brief centrifugation (1,300 rpm x 1 min), and cellular pellets were 
resuspended in Cytoplasmic Extract (CE) buffer supplemented with HALT protease inhibitor cocktail 
(Thermo Fisher, Rockford, IL). Samples were incubated for 5 min at 4°C and centrifuged at 1,300 rpm for 
1 min. Supernatants were moved to new tubes are stored at -80°C. 
For IL15Rα-IL15 detection by ELISA, the Mouse IL-15/IL-15R Complex ELISA Ready-SET-Go! kit 
(eBioscience, San Diego, CA) was used. All samples were 10-fold serially diluted and each dilution was 
done in duplicate. Each kit included a purified protein standard which was used to establish a standard 
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curve. An ELx800 Absorbance Microplate Reader (BioTek Instruments, Winooski, VT) was used to detect 
absorbance at 450 nm. 
Western Blot 
For Western Blot analysis, samples were transferred from the SDS-PAGE gels (precast Mini-PROTEAN 
TGX gels by Bio-Rad, Hercules, CA) to Millipore Immobilon-P Transfer membrane (Millipore, Billerica, 
MA) using the semi-dry transfer method (Trans-Blot® SD Semi-Dry Transfer Cell by Bio-Rad, Hercules, 
CA). Membranes were blocked in 4% skim milk in PBS. Antibodies were diluted in PBST/0.5% BSA. For 
IL15 detection, anti-IL15-biotin antibody from eBioscience (San Diego, CA) was used, coupled with IRDye 
800CW Streptavidin (SA-IRD800) from LI-COR (LI-COR Biosciences, US). For IL-15Rα detection, 
Mouse IL15 R alpha Affinity Purified Polyclonal Ab (R&D Systems, Minneapolis, MN) was used as a 
primary antibody, Rabbit polyclonal Antibody to Goat IgG - H&L (Biotin) (Abcam, Cambridge, MA) was 
used as a secondary antibody and finalized with SA-IRD800 as described previously. Blots were visualized 
on the Odyssey Infrared Imaging System (LI-COR Biosciences, US). Molecular weight markers used were 
Broad Range Prestained SDS-PAGE Standards from Bio-Rad (Hercules, CA). In each repeat of the 
experiment two separate, identically loaded SDS-PAGE gels were run, samples from each gel were 
transferred to a corresponding membrane, one of which was stained for IL15, and the other for IL15Rα. 
CTLL-2 cell proliferation assay 
MTT reagent (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) and detergent were purchased 
from ATCC (Manassas, VA). Confluent RK-13 cells in 6-well plates were infected with vMyx-IL15Rα-
tdTr or vMyx-tdTr at MOI=5. At 24h and 48 h p.i., cell-free media was collected and stored at -80°C. 
CTLL-2 cells were propagated overnight at 37°C, 5% CO2 in complete RPMI media with no added 
cytokines. Next, CTLL-2 cells were collected by centrifugation and resuspended at 50,000 cells per well in 
a 96-well plate in 100 μL complete RPMI containing either 10-9M IL-2, 10-9M TCR-IL15Rα (fusion of the 
m33 TCR with IL15Rα-IL15, “m33-superfusion” [32]), vMyx-tdTr or vMyx-IL15Rα-tdTr infected cell 
media. The cells were cultured for 48 h, and then 10 μL MTT was added per well, and the cells were 
incubated at 37°C, 5% CO2 for three more hours, and then 100 μL per well detergent was added, and the 
plate was incubated at room temperature overnight. To estimate CTLL-2 cell proliferation in different 
conditions, absorbance at 570 nm in each well was read using an ELx800 universal microplate reader (Bio-
Tek Instruments, Winooski, VT). 
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Animals 
C57BL/6 and C57BL/6 RAG1-/- mice originally purchased from The Jackson Laboratory (Bar Harbor, ME, 
USA) were maintained as colonies and housed in the animal facilities at the University of Illinois. Mice 
were used in experiments when they were 2-5 months old. All animal studies were approved by the 
Institutional Animal Care and Use Committee at the University of Illinois Urbana-Champaign (PHS 
Assurance A3118-01, AAALAC, International Accreditation #00766). Anesthesia was used during tumor 
cell and virus injections, and all efforts were made to minimize suffering. 
Subcutaneous tumor establishment and treatment 
B16-F10 melanoma cells were harvested and washed twice with Hanks Balanced Salt Solution (HBSS, 
Cellgro Mediatech Inc., Manassas, VA). Prior to all procedures, mice were anesthetized by isoflurane 
(Aerrane, Baxter, Deerfield, IL) inhalation using the classic vaporizer unit by E-Z Systems (Palmer, PA). 
Shaved mice received 1x 106 tumor cells in 100µl HBSS subcutaneously into the right flank. After 7 days, 
when tumors usually reach a volume of approximately 100 mm3, mice were assigned to treatment groups 
and received an intratumoral (i.t.) injection of virus. At this time, tumors were directly injected with 2.6×107 
PFU of sucrose-pad purified vMyx-IL15α-tdTr, vMyx-IL-15-tdTr or vMyx-tdTr that was in a final volume 
of 50 μl. A separate set of mice received 50 ul PBS i.t. An additional i.t. inoculation of each virus (2.6×107 
PFU) occurred 3 days later (day 10 post-implantation). For those tumors that were large, the inoculum was 
injected into at least three different sites to introduce the virus throughout the mass. Prior to all repeated 
tumor injections with either virus or PBS, animals were anesthetized by isoflurane inhalation as described 
earlier. All animals were single housed upon tumor cell implantation and during all subsequent 
experimental manipulations.  
Tumor growth was monitored by measuring tumor length, width and height with a caliper. Tumor volume 
was calculated as ((length) x (width) x (height))/2. Mice were monitored daily. Mice were humanely 
euthanized when tumors reached the volume of 3000 mm3, or showed lethargy or signs of pain, or when 
animal lost 25% baseline body weight. Mice were euthanized by CO2 asphyxiation followed by cervical 
dislocation. In some experiments, samples from some mice were collected 3 days after final virus treatment 
for histological analysis, and other mice in each treatment group were monitored until they reached a 
criterion for euthanasia.  
Tissue sections and immunostaining 
After the mice were euthanized, their subcutaneous tumors were snap-frozen in OCT medium for 
cryosectioning and immunostaining. Eight µm cryosections were taken. Primary antibodies used for 
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staining were: 4D11 (rat anti-Ly-49G2, BD Pharmingen, San Jose, CA), rabbit anti-CD3 (Abcam, 
Cambridge, MA), rat anti-CD8 (eBioscience, San Diego, CA), rat anti-CD4 (Abcam, Cambridge, MA). 
Secondary antibodies used: biotin rabbit anti-rat and biotin goat anti-rabbit (Vector, Burlingame, CA). For 
immunostaining, slides were fixed in cold 95% ethanol and blocked with Superblock (Thermo Scientific, 
Rockford IL). Sections were then incubated with a primary antibody in PBS + 20% glycerol (PBSG) 
overnight, washed with PBS + 0.1% Tween-20 (PBST), and incubated with biotinylated secondary antibody 
in PBST for 4 h. Slides were washed and incubated with streptavidin-Alexa Fluor 594 (Invitrogen, 
Carlsbad, CA) or streptavidin-Alexa Fluor 488 (Jackson ImmunoResearch, West Grove, PA) and DAPI 
(Invitrogen, Carlsbad, CA). Control slides omitting the primary antibody were negative for Alexa Fluor 
594 or Alexa Fluor 488. Images were obtained with an Olympus BX-51 microscope at 20x magnification. 
Data Analysis 
GraphPad Prism software (La Jolla, CA) was used for all statistical analyses and graph presentation. 
Survival data were recorded from the time of the tumor cell implantation until euthanasia and were plotted 
using a Kaplan-Meier curve. Survival treatment groups were compared with a Log-rank (Mantel-Cox) test. 
Virus growth curves were analyzed by two-way ANOVA, ELISA data were analyzed by t-test at 
corresponding time points, the bioassay of IL-15 activity was analyzed by one-way ANOVA, and 
histological cell counts were analyzed by one-way ANOVA with Bonferroni planned comparisons. 
Significance was considered p < 0.05.  
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2.3 Results 
Murine melanoma and glioma cell lines are permissive for recombinant myxoma virus infection 
Prior to testing the therapeutic capacity of the recombinant IL15Rα-IL15 virus (vMyx-IL15Rα-tdTr), we 
tested its capacity to infect relevant murine cancer cell lines in vitro. Multi-step growth curves of vMyx-
IL15Rα-tdTr and the previously characterized vMyx-tdTr control virus [29], showed similar patterns of 
permissiveness in various cell lines that were tested (Figure 2.2). Melanoma cell lines (B16-F10 and 
B16.SIY) were as permissive as the positive control rabbit cell line RK-13. For all three cell lines, infectious 
viral particles were formed by 12 h post infection, and maximal viral titer was typically obtained at the 48 
h time point. vMyx-IL15Rα-tdTr and vMyx-tdTr showed a different growth phenotype in the glioma cell 
line (GL261) and produced lower viral titers (Figure 2.2B). Based on the observation that the insertion of 
the IL15Rα-IL15 gene did not impact the infectivity of the virus, vMyx-IL15Rα-tdTr was considered a 
useful system to deliver functional IL15Rα-IL15 fusion protein to B16 tumors. 
IL15Rα-IL15 fusion protein is expressed and secreted in vitro by virus infected cells 
To determine if cells infected with vMyx-IL15Rα-tdTr were capable of secreting IL15Rα-IL15 fusion 
protein, we examined the culture media and cell extracts of infected cells using an ELISA specific for the 
IL15/IL15R complex. IL15Rα-IL15 was detected in both supernatants and cell extracts of vMyx-IL15Rα-
tdTr infected RK-13 cells (MOI=5) as compared to the control non-cytokine expressing virus vMyx-tdTr 
(Figure 2.3A). The peak of cell-associated expression of the fusion protein occurred at 12 h post-infection 
(mean value of 73 ng/ml), while secreted levels peaked at 48 h post-infection (mean value of 663 ng/ml). 
IL15Rα-IL15 was present in ten-fold higher levels in cellular supernatants versus cell-associated. As would 
be expected, cells infected with non-cytokine expressing virus (vMyx-tdTr) did not show measurable levels 
of IL15Rα-IL15. The presence of IL15 and IL15Rα domains was also confirmed by Western blot of 
supernatants and cell extracts (Figure 2.3B). These findings showed that the IL15Rα-IL15 gene that was 
stably inserted into myxoma virus was expressed and that the fusion protein was secreted from infected 
cells at high levels (over 500 ng/ml). 
IL15Rα-IL15 fusion protein secreted by vMyx-IL15Rα-tdTr infected cells is functionally active 
Functional activity of the IL15Rα-IL15 fusion protein in the supernatants of virus-infected cells was 
assayed by its ability to induce proliferation of cytokine-dependent CTLL-2 cells (Figure 2.4). CTLL-2 is 
a clone of T cells that requires IL-2 or other growth-promoting cytokines for proliferation [35]. MTT cell 
proliferation assays showed that CTLL-2 cells cultured in medium supplemented with supernatants of 
vMyx-IL15Rα-tdTr infected cells proliferated to the similar extent as CTLL-2 cells incubated with 
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recombinant IL-2 (10nM) or a purified fusion protein of IL15Rα-IL15 and a single-chain TCR m33 (10nM) 
[32]. In contrast, CTLL-2 cells cultured with supernatant of the control virus vMyx-tdTr were not stimulated 
to proliferate.  
Treatment with IL15Rα-IL15 fusion protein expressing myxoma virus results in increased presence 
of NK cells in tumors of RAG1-/- mice 
We next tested whether this new recombinant virus would affect cellular immune responses in vivo. 
Because NK cells are responsive to IL15 [36], we investigated whether treatment with vMyx-IL15Rα-tdTr 
was associated with the presence of NK cells in subcutaneous tumors of RAG1-/- mice, which have NK 
cells but no T or B cells. Accordingly, RAG1-/- mice bearing established subcutaneous B16-F10 tumors 
were injected intratumorally (i.t.) with vMyx-IL15Rα-tdTr, vMyx-tdTr or PBS on days 7 and 10 post tumor 
cell injection. Tumor sections of mice treated with the virus expressing IL15Rα-IL15 fusion protein showed 
dramatic and significant increase in numbers of infiltrating NK cells, compared to vMyx-tdTr and PBS 
treated tumor (Figure 2.5). This evidence suggests a role of NK cells as a component of the host immune 
system that may contribute to an antitumor effect. 
vMyx-IL15Rα-tdTr treatment enhances both NK cell and T cell recruitment to subcutaneous tumors 
in C57BL/6 mice 
To determine the effects of the virus in fully immunocompetent animals, we repeated the experiment using 
C57BL/6 mice. C57BL/6 mice with subcutaneous B16-F10 tumors were injected intratumorally with 
vMyx-IL15Rα-tdTr, vMyx-tdTr or PBS on days 7 and 10 post tumor cell injection. Similar to the effect 
observed in RAG1-/- mice, C57BL/6 mice treated with vMyx-IL15Rα-tdTr also had significant intra-tumor 
infiltration of NK cells, compared to both tdTomato expressing virus and PBS treatment (Figure 2.6A, B). 
In addition, T cell infiltration mirrored that of NK cells (Figure 2.6C, D). Analysis of T cell subsets in this 
response revealed that most tumor infiltrating T cells were CD8+, although CD4+ cells were also elevated 
in vMyx-IL15Rα-tdTr treated tumors compared to controls (Figure 2.7). 
Mice bearing subcutaneous melanoma tumors live longer when treated with IL15Rα-IL15 fusion 
protein-expressing virus compared to control viruses 
For survival experiments, mice with established B16-F10 s.c. tumors were treated the same way as 
described for histological analysis (intratumoral virus treatment on days 7 and 10 post tumor cell injection) 
and were monitored for survival. For RAG1-/- mice, treatment groups were vMyx-IL15Rα-tdTr, vMyx-
IL15-tdTr, vMyx-tdTr and PBS. Without any treatment (PBS), B16-F10 grows as an exceptionally 
aggressive tumor, with a median survival of 17 days. A small survival benefit was observed in the 
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tdTomato-only expressing virus group, similar to values obtained in a slightly different experimental setting 
[30]. Addition of the IL15 alone to the virus construct did not result in any improvement above this survival 
in RAG1-/- mice. However, addition of the IL15Rα-IL15 fusion protein improved therapeutic efficacy of 
myxoma virus compared to the other virus controls, including myxoma virus that expressed only the native 
IL15 domain (Figure 2.8). vMyx-IL15Rα-tdTr treatment resulted in tumor stabilization in the majority of 
animals until day 20, while mice given other treatments were succumbing to tumors at this point (Figure 
2.8A). For C57BL/6 mice, treatment groups were vMyx-IL15Rα-tdTr, vMyx-tdTr and PBS. The antitumor 
effect of vMyx-IL15Rα-tdTr in immunocompetent animals showed the same pattern as in RAG1-/- mice, 
with overall longer median survival in corresponding groups (Figure 2.9). The effect on both strains is 
especially notable given that the time of treatment was when the tumors were already established and at the 
start of their aggressive growth phase. 
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2.4 Discussion 
IL15 has been proposed as a useful cytokine for immunotherapy for cancer, and the complexing of IL15 
with its receptor alpha component has been shown to enhance its biological activity. We therefore modified 
a viral system to deliver the fusion protein of IL15Rα-IL15, employing a myxoma virus vector with a strong 
safety profile. We confirmed that the vMyx-IL15Rα-tdTr virus has the same ability to infect melanoma 
cells as the previously characterized vMyx-tdTr control virus, and that it secretes biologically active 
IL15Rα-IL15.  
IL15Rα-IL15 could potentially be delivered to tumors by a variety of means. For example, Bessard et al. 
delivered an IL15Rα-IL15 fusion protein by three systemic injections, prolonging the survival with a B16-
F10 model for 7 days [28], and Dubois et al. injected IL15 preassociated with IL15RFc, repeated as many 
as nine times, prolonging survival of B16-F10 bearing mice for 5 days [24]. In comparison, in the present 
study two injections of vMyx-IL15Rα-tdTr resulted in a prolongation of survival of 12 days in RAG1-/- 
mice and 20 days in C57BL/6 mice. Delivery by a viral vector results in secretion of virally encoded 
proteins peaking at 48-72 h and persisting for up to a week [31], so most likely fewer treatments would be 
needed to maintain the presence of the cytokine in the tumor environment.  
In the survival experiments in RAG1-/- mice we compared effects of vMyx-IL15Rα-tdTr with vMyx-IL15-
tdTr [29] (virus expressing IL15 but without the IL15Rα fusion component) as well as non-cytokine 
expressing vMyx-tdTr. Based on recent literature [23][37][38][39][40], adding the IL15Rα significantly 
improves IL15 effects compared to the cytokine itself. This was confirmed in our experimental setting: 
IL15-only expressing virus, consistent with published data [30], showed therapeutic effect against murine 
melanoma tumors in the RAG1-knockout background indistinguishable from vMyx-tdTr. Hence, for most 
of our other studies we compared the novel recombinant virus with the variant that was closer to wild type, 
expressing only the fluorescent protein. 
Both NK cells and CD8+ T cells responded to vMyx-IL15Rα-tdTr. In RAG1-/- mice, histological analysis 
revealed robust NK cell accumulation in the tumors of the treated animals. Previous studies have done 
depletion of NK cells prior to treatment to show that NK cells contribute to the antitumor effect of 
IL15/IL15R [28][41]. In some models, the effect of IL15Rα-IL15 is more dependent on CD8+ T cells 
[27]. In immunocompetent C57BL/6 mice, both NK cells and CD8+ T cells heavily infiltrated the tumors 
following vMyx-IL15Rα-tdTr treatment. Consistent with the idea that both cell types play a role in the 
effects of vMyx-IL15Rα-tdTr, treated C57BL/6 mice survived longer than treated RAG1-/- mice (43 days 
versus 29 days, p < 0.05). 
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Elpek et al. observed that sustained activation of NK cells by IL15/IL15R treatment (5 injections over 2 
weeks) can lead to functional exhaustion of effector functions of NK cells [42]. Viral delivery by myxoma 
virus produces IL15Rα-IL15 secretion that is intermediate between a rapidly cleared systemic injection and 
chronic exposure. Future studies could determine an optimal interval for repetitive treatments to minimize 
NK cell exhaustion. 
In addition to the delivery of IL15Rα-IL15, the myxoma construct itself may contribute to an enhanced 
immune response. Previously we demonstrated the feasibility of combining adoptive T cell therapy with 
concurrent administration of an oncolytic virus [31]. There are at least three potential mechanisms by which 
myxoma virus could kill susceptible tumor cells: First, virus can directly kill tumor cells by viral oncolysis; 
second, local production of antitumor cytokines caused by viral infection can lead to recruitment and 
activation of immune cells that better recognize and kill tumor cells; third, killed cancer cells can be a more 
potent source of cross-presented tumor peptides by tumor stroma to further enhance the acquired antitumor 
immune response [43]. Manipulation of tumor microenvironment is an important strategy to improve 
adoptive T cell therapy and eliminate occurrence of antigen loss variants (ALV), cells that lose the T cell 
reactive epitope and eventually lead to tumor outgrowth [31]. We hypothesized that delivery of a highly 
functional and potent IL15Rα-IL15 cytokine, especially in the context of viral infection, would provide a 
necessary boost to immune cells in driving their functional antitumor activities. Potential combination 
therapy along with the immunomodulating activities of anti-PD1/PDL1 antibodies, might provide an even 
more robust initial response and elimination of ALVs [44][45][27]. 
In summary, the use of delivery systems such as vMyx-IL15Rα-tdTr, and related genetically modified 
viruses, has the potential to improve clinical outcomes of cancer therapy.  
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2.6 Figures 
 
Figure 2.1. Recombinant plasmid for modifying WT myxoma virus and generating vMyx-IL15Rα-
tdTr. Plasmid pBS-IL15Rα-IL15-tdTomatoRed (6267bp) is based on the pBluescript backbone on which 
M135 and M136 partial viral gene sequences are flanking genes for IL15Rα-IL15 fusion protein and 
tdTomato red fluorescent protein, both under control of vvSynE/L viral promoters. This expression cassette 
is flanked by partial viral gene sequences for the purpose of being transfected into the WT vMyx-Lau virus 
genome between genes M135 and M136. 
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Figure 2.2. Melanoma and glioma cell lines are permissive to recombinant myxoma virus infection. 
Cell lines (A) RK-13, (B) GL261, (C) B16-F10, (D) B16.SIY, were infected with either vMyx-tdTr or 
vMyx-IL15Rα-tdTr at a multiplicity of infection (MOI) of 0.1 to obtain multi-step growth curves. At 0, 12, 
24, 48, 72 or 96 h post-infection (p.i.), cells were harvested and lysed, and the viral titer was determined by 
titration on RK-13 cells. Error bars represent SEM from 3 replicates for each cell line. There was a 
significant effect of time for each of the cell lines (p < 0.001).  
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Figure 2.3. IL15Rα-IL15 fusion protein is present in the supernatants and extracts of cells infected 
with vMyx-IL15Rα-tdTr. Confluent RK-13 cells in 6-well plates were infected with vMyx-IL15Rα-tdTr 
or vMyx-tdTr at MOI=5. At indicated times post-infection, media was collected and cells were scraped, 
lysed and cytoplasmic extract was harvested. (A) ELISA. Mean ELISA values with SEM for triplicates of 
the same condition are presented, and the experiment was repeated with similar results. There was a 
significant increase in IL15Rα-IL15 fusion protein in supernatants of vMyx-IL15Rα-tdTr treated cells 
compared to vMyx-tdTr treated ones at corresponding timepoints (* - p < 0.05). (B) Western Blot. At 48 h 
post-infection, membranes blotted with supernatants and cell extracts of virus infected cells were stained 
for IL15 (left panel) or IL15Rα (right panel). Experiment was repeated five times with similar results. (SNT 
– supernatant, CE – cell extract) 
 
47 
 
 
 
 
Figure 2.4. IL15Rα-IL15 fusion protein secreted by virus-infected RK-13 cells is functionally active. 
Confluent RK-13 cells in 6-well plates were infected with vMyx-IL15Rα-tdTr or vMyx-tdTr at MOI=5. At 
24 h and 48 h p.i., cell media were collected. CTLL-2 cells were incubated with un-supplemented media 
(RPMI), three positive controls (media supplemented with 10% T-Stim (RPMI + T-Stim), 10-9M IL-2 or 
10-9M TCR-IL15-IL15Rα fusion protein (TCR-IL15Rα)), or supernatants from cells infected with vMyx-
tdTr or vMyx-IL15Rα-tdTr. CTLL-2 cell proliferation was analyzed by the MTT assay. Experiments were 
performed in triplicate for each treatment, and mean values with SEM are presented. Positive controls and 
supernatants from RK-13 cells infected with vMyx-IL15Rα-tdTr (marked by *) showed significant 
functional IL-15 activity, but supernatant from vMyx-tdTr infected RK-13 cells did not.  
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Figure 2.5. NK cell infiltration of subcutaneous B16-F10 tumors 3 days after intratumoral virus 
treatment in RAG1-/- mice. RAG1-/- mice (n = 3 per group) were implanted with unilateral subcutaneous 
B16-F10 tumor cells. The first dose of the virus (2.6×107 PFU i.t.) was given on day 7 (when tumors reached 
approximately 100mm3) and the second dose was given on day 10. Treatment groups are: 1. vMyx-IL15Rα-
tdTr 2. vMyx-tdTr 3. PBS. Mice were euthanized 3 days after the final virus treatment and tumor sections 
were analyzed for presence of NK cells by immunostaining for Ly-49G2 (4D11 antibody). Representative 
tumor sections are shown. (A) Staining for NK cells in tumors. Red – 4D11-positive stain, Blue – DAPI. 
Scale bar = 50 micrometers. (B) Estimated number of NK cells per square millimeter of a tumor section for 
each condition. Presented values are mean cell count in tumors from three mice, with SEM. One-way 
ANOVA showed significant increase in NK cell accumulation in vMyx-IL15Rα-tdTr treated tumors 
compared to both vMyx-tdTr and PBS treatments (* - p < 0.05). 
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Figure 2.6. NK and T cell infiltration of subcutaneous B16-F10 tumors 3 days after intratumoral 
virus treatment in C57BL/6 mice. C57BL/6 mice (n = 3 per group) were implanted with unilateral 
subcutaneous B16-F10 tumor cells. The first dose of the virus (2.6×107 PFU i.t.) was given on day 7 (when 
tumors reached approximately 100mm3) and the second dose was given on day 10. Treatment groups are: 
1. vMyx-IL15Rα-tdTr, 2. vMyx-tdTr, 3. PBS. Mice were euthanized 3 days after the final virus treatment 
and tumor sections were analyzed for presence of NK cells and T cells by immunostaining for Ly-49G2 
(4D11 antibody) and CD3, respectively. Representative tumor sections are shown. (A) Staining for NK 
cells in tumors. Red – 4D11-positive stain, Blue – DAPI. Scale bar = 50 micrometers. (B) Estimated number 
of NK cells per square millimeter of a tumor section for each condition, mean values and SEM from 3 mice 
per group. One-way ANOVA showed significant increase in NK cell accumulation in vMyx-IL15Rα-tdTr 
treated tumors compared to both vMyx-tdTr and PBS treatments (* - p < 0.05). (C) Staining for T cells in 
tumors. Green – CD3-positive cells, Blue – DAPI. Scale bar = 50 micrometers. (C) Estimated number of T 
cells per square millimeter of a tumor section for each condition, mean values and SEM from 3 mice per 
group. One-way ANOVA showed significant increase in T cell accumulation in vMyx-IL15Rα-tdTr treated 
tumors compared to both vMyx-tdTr and PBS treatments (* - p < 0.05). 
  
50 
 
 
 
 
Figure 2.6 (cont’d). NK and T cell infiltration of subcutaneous B16-F10 tumors 3 days after 
intratumoral virus treatment in C57BL/6 mice. 
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Figure 2.7. Analysis of subsets of T cells infiltrating subcutaneous B16-F10 tumors 3 days after 
intratumoral virus treatment in C57BL/6 mice. C57BL/6 mice (n = 3 per group) were implanted with 
unilateral subcutaneous B16-F10 tumor cells. The first dose of the virus (2.6×107 PFU i.t.) was given on 
day 7 (when tumors reached approximately 100mm3) and the second dose was given on day 10. Treatment 
groups are: 1. vMyx-IL15Rα-tdTr, 2. vMyx-tdTr, 3. PBS. Mice were euthanized 3 days after the final virus 
treatment and tumor sections were analyzed for presence of T cells by immunostaining for CD4 and CD8 
markers. Representative tumor sections are shown. (A) Staining for CD8+ T cells in tumors. Green – CD8-
positive cells, Blue – DAPI. Scale bar = 50 micrometers. (B) Staining for CD4+ T cells in tumors. Red – 
CD4-positive cells, Blue – DAPI. Scale bar = 50 micrometers. 
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Figure 2.8. Prolonged survival of RAG1-/- mice bearing subcutaneous B16-F10 tumors treated with 
vMyx-IL15Rα-tdTr intratumorally. RAG1-/- mice (10 mice in vMyx-IL15Rα-tdTr and PBS and 6 mice 
in vMyx-IL15-tdTr and vMyx-tdTr treatment groups) were implanted with subcutaneous B16-F10 tumor 
cells. 7 days later, when tumors reached approximately 100 mm3, virus was inoculated intratumorally (i.t.) 
with 2.6×107 PFU vMyx-IL15Rα-tdTr, vMyx-IL15-tdTr, vMyx-tdTr or PBS. Mice received a second i.t. 
inoculation of 2.6×107 PFU of each virus on day 10. (A) Growth of individual tumors. Dashed lines 
designate time of virus treatment, and growth of tumors was measured every 2 days. (B) Kaplan–Meier 
survival curve of the same experimental subjects. Numbers next to corresponding survival curves designate 
median survival time (days). (* - p < 0.05 for vMyx-IL15Rα-tdTr treated group compared to other vMyx, 
as well as PBS treatment) 
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Figure 2.9. Prolonged survival of C57BL/6 mice bearing subcutaneous B16-F10 tumors treated with 
vMyx-IL15Rα-tdTr intratumorally. C57BL/6 mice (5 mice per group) were implanted with 
subcutaneous B16-F10 tumor cells. 7 days later, when tumors reached approximately 100 mm3, virus was 
inoculated intratumorally (i.t.) with 2.6×107 PFU vMyx-IL15Rα-tdTr, vMyx-tdTr or PBS. Mice received a 
second i.t. inoculation of 2.6×107 PFU of each virus on day 10. (A) Growth of individual tumors. Dashed 
lines designate time of virus treatment, and tumor size was measured every 2 days. (B) Kaplan–Meier 
survival curve of the same experimental subjects. Numbers next to corresponding survival curves designate 
median survival time (days). (* - p < 0.05 for vMyx-IL15Rα-tdTr treated group compared to PBS) 
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CHAPTER THREE  
MYXOMA VIRUS AND T CELL COMBINATION THERAPY 
3.1 Introduction 
Adoptive T cell therapy and other immunotherapies for cancer have shown promise as monotherapies, but 
cancer recurrence remains one of the big issues [1]. Antigen loss variants (ALVs), sub-populations of cancer 
cells that no longer express the target antigen that may escape destruction by the T cells and cause 
reemergence of the tumor, remain a challenge for tumor-antigen specific therapies [2]. It is evident that 
successful treatment of different cancers will have to involve some form of combination therapy [3] [4], 
and many clinical trials are underway to test combinations of previously approved and new treatments [5] 
[6] [7].  
Oncolytic viruses mostly induce immunogenic cancer cell death, leading to release of damage- and 
pathogen-associated molecular patterns (DAMPs and PAMPs) along with tumor-associated antigens 
(TAAs) at the tumor site [8] [9]. These events activate dendritic cells and elicit adaptive antitumor immunity 
[10]. Oncolytic viral therapy also has the potential to increase pro-inflammatory cytokines and chemokines 
and decrease immunosuppressive cytokines in the tumor environment [11].  
Successful elimination of solid tumors and prevention of their recurrence from outgrowth of ALVs is 
dependent on destroying cancer cells as well as non-transformed stromal cells in tumor environment that 
support tumor growth [12] [13]. Antigen release from dying cancer cells by irradiation, chemotherapy or 
other methods can increase presentation of tumor antigen on stromal cells, which contributes to enhanced 
killing by adoptively transferred T cells [14]. Successful elimination of tumors that expressed high levels 
of TAAs by cytotoxic T cells was observed in both subcutaneous and brain tumor mouse models [14] [15].  
In this study, we first describe results of an experiment in which virus expressing IL15Rα-IL15 construct 
was combined with naïve CD8+ T cells to treat a murine melanoma, B16-F10. This combination did not 
produce a pronounced antitumor effect, so we next tested virus therapy in combination with T cells specific 
for an antigen expressed on the surface of the cancer cells. In order to do that, we used a well characterized 
2C T cell system that recognizes SIY antigenic peptide on the context of Kb (mouse MHC molecule) on 
B16-F10 melanoma cells transduced to express SIY (B16.SIY). The combined therapies showed a 
significant survival benefit, but mice still succumbed to the tumors, presumably because of antigen loss 
variants (ALV), as previously described [16] [17]. With the idea of increasing tumor antigen presentation 
in initial phase of T cell antitumor response, we generated a construct to create a new virus, vMyx-SIY-
tdTr, which would have desirable properties of specifically targeting cancer cells, as well as expressing the 
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SIY antigen in the infected cell and making antigen available to the tumor stroma. We hypothesized that 
combination of viral effect of enhancing the attenuated immune response and increasing presence of T cell 
specific antigen in the tumor would lead to better control of the tumor, or even tumor-free survival. Here 
we describe initial phases of the creation of the new virus. 
  
56 
3.2 Materials and methods 
DNA construct  
pBS-IL15Rα-IL15-tdTomatoRed, used for generating vMyx-IL15Rα-tdTr was described in the previous 
chapter. Plasmid for expressing SIY and tdTomato as a single transcriptional unit under the vvSynE/L 
promoter, termed pBS-SIY-tdTomato, was created in a similar fashion. Briefly, PCR product isolated from 
vMyx-tdTr  [18] was ligated into pBluescript (ATCC, Manassas, VA) using the T4 Ligase (Invitrogen, 
Carlsbad, CA) following sequential digestion with HindIII and BamHI (New England BioLabs, Ipswich, 
MA). tdTomato was cloned out of the plasmid provided by Dr. Brian Freeman (University of Illinois) using 
primers: forward 5'- GCA AGA TCT ATG GTG AGC AAG G – 3’ and reverse: 5’- CCT GAA TTC TTA 
CTT GTA CAG CTC G – 3’ and cloned into the existing pBluescript construct using BglII and EcoRI (New 
England BioLabs, Ipswich, MA). SIYRYYGL triplicate sequence was isolated from pMFG-SIY-EGFP 
(similar to  [12]) using primers: forward 5’- CGG GGG TGG ACC ATC CTC TAG AGA TCT ATG TTG 
– 3’ and reverse: 5’- GCA AGA TCT GGT GGC GAC CGG TGG ATC – 3’ and cloned into the existing 
construct using a single BglII restriction site. Orientation and copy number of SIY triplicates was confirmed 
by sequencing the resulting pBS-SIY-tdTomato plasmid (Figure 3.4). This construct will eventually be used 
to engineer the SIY-tdTomato expressing myxoma virus.  
Recombinant virus 
Creation and characterization of recombinant vMyx-IL15Rα-tdTr was described in detail in the previous 
chapter. Briefly, vMyx-IL15Rα-tdTr was created by homologous recombination in RK-13 cells infected 
with wild type (WT) vMyx-Lau followed by transfection with the engineered recombination vector pBS-
IL15Rα-IL15-tdTomatoRed. Genes for the IL15Rα-IL15 fusion protein and tdTomato, both under control 
of identical vvSynE/L promoters, were inserted between M135 and M136 myxoma virus genes. 
Cell culture and reagents 
The murine melanoma cell line, B16-F10 was purchased from ATCC (Manassas, VA). B16.SIY was 
derived from B16-F10 cells retrovirally transduced to express green fluorescent protein (GFP) as a fusion 
protein with SIYRYYGL (SIY)  [12,19] and was a gift from Dr. Thomas Gajewski (University of Chicago, 
Chicago, IL).  
Cancer cell lines were cultured in complete Roswell Park Memorial Institute (RPMI) 1640 medium 
containing 5 mM HEPES, 1.3 mM L-glutamine, 50 µM 2-ME, penicillin, streptomycin and 10% fetal 
bovine serum (FBS) at 37°C and 5% CO2. 
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Animals 
C57BL/6 and C57BL/6 RAG1-/- mice originally purchased from The Jackson Laboratory (Bar Harbor, ME, 
USA) were maintained as colonies and housed in the animal facilities at the University of Illinois. Colonies 
of 2C T cell receptor (TCR) transgenic mice on the C57BL/6 background (provided by J Chen, 
Massachusetts Institute of Technology, Cambridge, MA) are maintained as a heterozygous colony and 
screened for expression of the 2C TCR on Thy1.2+ peripheral blood cells with 1B2 clonotypic antibody by 
flow cytometry. Mice were used in experiments when they were 2-5 months old. All animal studies were 
approved by the Institutional Animal Care and Use Committee at the University of Illinois Urbana-
Champaign (PHS Assurance A3118-01, AAALAC, International Accreditation #00766). Anesthesia was 
used during tumor cell and virus injections, and all efforts were made to minimize suffering. 
Subcutaneous tumor establishment and treatment 
B16-F10 melanoma cells were harvested and washed twice with Hanks Balanced Salt Solution (HBSS, 
Cellgro Mediatech Inc., Manassas, VA). Prior to all procedures, mice were anesthetized by isoflurane 
(Aerrane, Baxter, Deerfield, IL) inhalation using the classic vaporizer unit by E-Z Systems (Palmer, PA). 
Shaved mice received 1x106 tumor cells in 100µl HBSS subcutaneously into the right flank. After 7 days, 
when tumors usually reach a volume of approximately 100 mm3, mice were assigned to treatment groups 
and received an intratumoral (i.t.) injection of virus. At this time, tumors were directly injected with 2.6×107 
PFU of sucrose-pad purified vMyx-IL15α-tdTr or PBS that was in a final volume of 50 μl. An additional 
i.t. inoculation of the virus (2.6×107 PFU) or PBS occurred 3 days later (day 10 post-implantation). For 
those tumors that were large, the inoculum was injected into at least three different sites to introduce the 
virus throughout the mass. Prior to all repeated tumor injections with virus or PBS, animals were 
anesthetized by isoflurane inhalation as described earlier. All animals were single housed upon tumor cell 
implantation and during all subsequent experimental manipulations.  
Tumor growth was monitored by measuring tumor length, width and height with a caliper. Tumor volume 
was calculated as ((length) x (width) x (height))/2. Mice were monitored daily. Mice were humanely 
euthanized when tumors reached the volume of 3000mm3, or showed lethargy or signs of pain, or when 
reaching 75% baseline body weight. Mice were euthanized by CO2 asphyxiation followed by cervical 
dislocation.  
Intracranial tumors establishment and treatment 
B16-SIY melanoma cells were harvested, washed twice with HBSS and stereotaxically infused into the 
brains of mice anesthetized with isoflurane, as described above. 2x103 B16.SIY cells in 300 nL HBSS were 
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infused into ventral striatum (from bregma: 0.5 mm rostral; 2.5 mm lateral; 4 mm ventral). Mice were 
euthanized at 75% of baseline body weight or signs of neurological impairment, lethargy or pain, in 
accordance with IACUC guidelines. 
Tumor bearing mice were stereotaxically injected intratumorally (i.t.) with approximately 1x106 PFU 
vMyx-IL15α-tdTr or PBS control in 0.7µL PBS. Some mice were euthanized 4 days post virus injection 
for analysis of tdTomatoRed expression (this time point was based on our previous studies  [16]).  
For adoptive 2C T-cell transfer, lymphocytes from spleens and lymph nodes of 2C TCR mice were prepared 
by mechanical tissue dissociation through nylon mesh followed by ACK buffer lysis of erythrocytes. Mixed 
lymphocytes were incubated at 37°C, 5% CO2 for 48h with 1µM SIY peptide and 5% rat ConA supe 
(RCAS) to activate and expand effector 2C T cells. Cells were then collected, washed with HBSS and an 
average of 5x106 of activated 2C T cells in 200µl HBSS was injected into the tail vein of mice 6 days 
following tumor cell infusion. Control mice were injected with 200µL HBSS. 
Tissue sections and immunostaining 
After the mice were euthanized, their brains with intracerebral tumors and draining lymph nodes were 
immersion fixed in 10% formalin to preserve tdTomato protein expression, and then snap-frozen in OCT 
medium for cryosectioning and immunostaining. Eight µm cryosections were taken. For tdTomatoRed 
visualization, slides were washed in filtered dH20 and PBS and briefly incubated with DAPI. Images were 
obtained with an Olympus BX-51 microscope at 10x and 20x magnification. 
Transient transfection and MVA infection 
B16-F10 and B16.SIY cells were plated in 6-well culture plates and upon reaching 90-95% confluency they 
were transfected with pBS-SIY-tdTomato or pBS-IL15Rα-IL15-tdTomato using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA). 9h after transfection with plasmid DNA, cells were infected with modified 
vaccinia Ankara (MVA) poxvirus (gift from Dr. Joanna Shisler’s laboratory, University of Illinois) at 
MOI=5. Inoculated cells were incubated with the virus in serum-free media at 37°C and 5% CO2 for 1h, 
rocking every 15 min. Cells were imaged and collected at 12 h and 36 h post-infection (p.i.). Fluorescent 
images in the Texas Red channel were taken by Olympus DP12 camera and cells were collected and 
analyzed by flow cytometry for presence of transiently expressed molecules.  
Flow cytometry  
Plasmid DNA transfected and MVA infected B16-F10 and B16.SIY cells in 6-well plates were trypsinized, 
washed in PBS and prepared for analysis on the Accuri C6 instrument. tdTomato expression was detected 
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in the FL2 channel. Additionally, cells were stained for the expression of mouse MHC Class I molecule Kb 
(anti-Kb-APC, eBioscience, San Diego, CA) and for the Kb-SIY complex using biotinylated soluble high-
affinity TCR, m67 [14] (provided by Dr. Jennifer Stone, Kranz laboratory, University of Illinois), followed 
by Streptavidin-APC (Invitrogen, Carlsbad, CA). Data were analyzed on the FCS Express software.  
Statistics  
GraphPad Prism software (La Jolla, CA) was used for all statistical analyses and graph presentation. 
Survival data were recorded from the time of the tumor cell implantation until euthanasia and were plotted 
using a Kaplan-Meier curve. Survival treatment groups were compared with a Log-rank (Mantel-Cox) test. 
Significance was considered p < 0.05. 
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3.3 Results 
Treatment with IL15Rα-IL15 fusion protein expressing myxoma virus and naïve T cells provides a 
survival benefit to mice with subcutaneous tumors 
In vitro assays described in previous chapter showed that vMyx-IL15Rα-tdTr is able to productively infect 
cells in culture and render them capable of secreting IL15Rα-IL15 fusion protein. We also showed an effect 
of the virus as a stand-alone therapy in RAG1-/- and C57BL/6 mice. The next step was to test the virus in 
vivo as a combination therapy with adoptively transferred immune cells. RAG1-/- mice bearing established 
B16-F10 tumors were treated with vMyx-IL15Rα-tdTr intratumorally alone or in combination with primary 
murine naïve cytotoxic T cells (CD8+ cells) intravenously. Treatment with cytokine fusion protein 
expressing vMyx-IL15Rα-tdTr significantly contributed to survival of mice bearing B16-F10 subcutaneous 
tumors, similarly as shown in the previous chapter (median survival of 36 days compared to 21 days for 
PBS only treated mice, Figure 3.1). Naïve cytotoxic T cells did not significantly contribute to increased 
survival of tumor bearing animals, either alone or in combination with the virus, although the two longest 
surviving mice were treated with the combination. 
Treatment with vMyx-IL15Rα-tdTr in combination with 2C T cells provides a survival benefit to 
mice with intracranial tumors 
After encouraging viral therapeutic effect with subcutaneous tumors, we sought to investigate the potential 
therapeutic effect of vMyx-IL15Rα-tdTr on established brain tumors. We also investigated a possible 
synergistic effect between the immunostimulatory protein expressing virus and tumor-specific T cells. For 
this purpose, we used the well-established 2C system, in which cytotoxic T cells equipped with the 2C T 
cell receptor specifically recognize and kill cancer cells engineered to express the SIY peptide [20]. Figure 
3.2 shows the survival of mice bearing B16.SIY intracranial tumors after treatment with vMyx-IL15Rα-
tdTr intratumorally and/or 2C T cells intravenously. We know from previously published studies [16] that 
2C T cell clone by itself prolongs survival of tumor bearing mice beyond 30 days after tumor cell implant 
in this model. Addition of the virus treatment showed a trend toward increased survival compared to the 
2C T cell only treated group (median survival of 37.5 vs. 33.5 days, respectively). All treated groups 
survived significantly longer than the PBS control.  
Figure 3.3 shows productive and selective infection of brain tumor tissue 4 days after virus treatment. 
Virally encoded fluorescent protein, tdTomato is expressed in virus infected tumor cells. No notable 
difference in virus spread was observed in the treatment group that was treated with 2C T cells in addition 
to the virus. 
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tdTomato is expressed from the pBS-SIY-tdTomato plasmid in transiently transfected cells 
With the idea of boosting the antitumor immunity by increasing the antigen presentation in the model tumor 
antigen SIY – 2C T cell system, we decided to create a myxoma virus that would specifically express SIY 
in the context of the tumor. After successfully cloning the fusion protein of SIY repeats and tdTomato into 
the pBS plasmid, the new construct, pBS-SIY-tdTomato was tested to ensure expression of the desired 
proteins from the virus-infected cells. In order to do that, we did a transient transfection of B16-F10 and 
B16.SIY cells with the plasmid, coupled with the infection by the MVA virus. Infection by a poxvirus MVA 
was necessary in order to drive expression of the genes from the viral promoter.  
tdTomato was visible by fluorescent microscopy in the Texas Red channel in transiently transfected and 
virus infected cells at 12 h p.i. (Figure 3.5A), and in even more cells at 36 h p.i. (Figure 3.5B). The trend 
of tdTomato expression in treated B16-F10 cells was confirmed by flow cytometry. At 12 h p.i., about 16% 
of cells were estimated positive for tdTomato (Figure 3.6A), while the fraction of tdTomato expressing 
B16-F10 cells was close to 33% at 36 h p.i. (Figure 3.6B). Cells transfected with pBS-IL15Rα-IL15-
tdTomato served as a positive control for tdTomato expression. 
B16.SIY cells were previously engineered to express SIY peptide [12], and were intended as a positive 
control for Kb-SIY complex staining by the high affinity TCR m67 [14]. Untreated cultured B16-F10 and 
B16.SIY cells express an undetectable level of the relevant MHC molecule, Kb (Figures 3.7A and B, black 
histograms). Transfection with the DNA and MVA infection led to upregulation of Kb on the surface of the 
cells; however DNA transfection alone caused the highest expression of Kb above background (75% 
positive cells), while simultaneous MVA infection somewhat reduced MHC expression (45% positive 
cells)(Figure 3.7A). Similar results were observed in B16.SIY cells (Figure 3.7B). Staining for Kb-SIY with 
soluble m67 TCR suggested surface presentation of the SIY peptide (7% of pBS-SIY-tdTomato and MVA 
treated B16-F10 cells were positive, compared to less than 1% for untreated B16-F10 cells, Figure 3.7C). 
Lack of Kb-SIY staining on constitutively expressing B16.SIY cells (Figure 3.7D, black histogram) could 
be due to low MHC levels in the no treatment group (compare with figure 3.7B). However, Kb-SIY should 
have been detectable in B16.SIY cells that had increased level of Kb (Figure 3.7D, green histogram). 
Modified treatment conditions and pretreatment with IFNγ will be necessary to unequivocally confirm Kb-
SIY staining on the surface of the cells. 
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3.4 Discussion 
It has been previously shown in our laboratory and by others that increasing tumor antigen expression can 
lead to tumor eradication. In the brain tumor model, adoptively transferred cytotoxic 2C T cells specific for 
the SIY peptide antigen presented by the cancer cells completely eliminated SIY-high expressing brain 
tumors and cured mice while mice with SIY-low tumors usually relapsed [15]. Tumor-antigen specific T 
cells were capable of eliminating even allogeneic tumors expressing the same antigen but non-cognate 
MHC molecules (H-2k), which prevents 2C T cells from directly recognizing them. This result confirmed 
that cross-presentation of the tumor antigen by stromal cells played a significant role in tumor elimination 
by the adoptively transferred T cells. Similarly, in the subcutaneous model, if cancer cells express only low 
levels of SIY, stromal cells are not destroyed by the transferred 2C T cells, and the tumor escapes as ALVs 
[14]. In addition, this study showed that treating tumors expressing low levels of antigen with local 
irradiation or a chemotherapeutic drug caused sufficient release of the antigen to sensitize stromal cells for 
destruction by T cells and subsequent tumor rejection. Proper timing of the T cell transfer was essential for 
the combination therapy success, since loading and cross-presentation of tumor antigen by the stromal cells 
in vivo peaked at 2 days after radiation or chemotherapy. We postulate that oncloytic effect of the virus 
could have a similar effect as radiation or chemotherapy observed in this study. The SIY-expressing 
construct needs to be inserted into the myxoma virus to allow testing of this hypothesis. 
The feasibility of combining an oncolytic virus with adoptive T cell therapy has been demonstrated by 
many groups [9] [21]. The Vile group showed that vesicular stomatitis virus (VSV) engineered to express 
chicken ovalbumin (OVA) mediated complete regression of B16 melanomas expressing OVA antigen in 
many mice, since treatment with recombinant virus developed potent anti-OVA immunity [22]. In another 
study by the same group, ACT combined with systemic administration of two engineered VSVs (OVA and 
endogenous melanocyte antigen glycoprotein 100 (gp100)-expressing variants) induced regression of 
established tumors in all treated mice [23]. Using a different strategy, chemokine CCL5-expressing vaccinia 
virus in combination with a cancer vaccine or activated T cells improved therapeutic effect in a murine 
colon cancer model [24]. Another group used an oncolytic vaccinia virus engineered to express a secretory 
bispecific T cell engager, an antibody based construct that recognizes the tumor cell surface antigen EphA2 
and CD3 molecule on the surface of T cells. The molecule secreted by the virus activates T cells in the 
proximity of the tumor, and it showed potent antitumor activity in the lung cancer xenograft model [25]. A 
study from our laboratory showed promise in combining adoptive immunotherapy and rapamycin-enhanced 
virotherapy, since rapamycin treatment did not impair T cell-mediated tumor destruction [16].  
Virus might act as an effective adjuvant for the expression of TAA to adoptively transferred, TAA-specific 
T cells by activation of antigen presenting cells (APCs) through signaling molecules such as MyD88, as 
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well as Type I and Type III interferon mediated signaling [23]. CD8α+ dendritic cells are particularly 
effective at acquiring antigen from dying cells, including tumor cells, and targeting antigen for cross-
presentation via the class I MHC processing pathway [26].  
Therapeutic approaches exploring multiple ways of activating antitumor immune response and enhancing 
antigen presentation are under active development. A poxvirus based therapeutic cancer vaccine that is 
currently in the phase III clinical trials, PROSTVAC , is designed to break immunological tolerance to 
prostate specific antigen (PSA) and initiate a robust immune response against prostate cancer [27]. Vaccinia 
and fowlpox virus based vectors are engineered to express PSA and a triad of human T-cell costimulatory 
molecules (the TRICOM triad: B7.1, ICAM-1, and LFA-3) [28]. Preclinical studies have shown that the 
vaccine's ability to treat tumors is largely dependent on CD8+ T cells, and partially dependent on CD4+ T 
cells and natural killer (NK) cells  [29]. Current clinical studies are analyzing the vaccine's ability to 
generate tumor-specific T cells. 
Additionally, a combination of oncolytic viruses with immunotherapeutic strategies aimed to disrupt tumor-
induced tolerance is an attractive strategy. In one recent study, the combination of replication competent 
VSV with anti-CTLA-4 monoclonal antibody led to elimination of tumor implants in the majority of 
animals, in a CD4+ and CD8+ T cell dependent manner [30]. In another very recently published study, 
localized therapy with oncolytic Newcastle disease virus (NDV) induced inflammatory immune infiltrates 
in distant tumors, making them susceptible to systemic therapy with an anti-CTLA-4 antibody. The effect 
was dependent on CD8+ cells, NK cells and type I interferon [31]. These studies provide strong evidence 
that such combinations would be useful in the clinical setting.  
In summary, an ideal immunotherapeutic intervention against cancer would have to (1) stimulate the 
presentation of TAAs to T cells, while (2) counteracting the immunosuppressive activity of tumor 
microenvironment [32]. We believe that combination therapy of TAA-expressing virus and ACT may have 
synergistic effects and will lead to improved effectiveness of both treatments. 
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3.6 Figures 
 
Figure 3.1 – Survival and tumor growth in RAG1-/- mice with subcutaneous B16-F10 treated with 
vMyx-IL15Rα-tdTr and naïve CD8+ T cells. RAG1-/- mice were implanted with unilateral subcutaneous 
B16-F10 tumor cells. Adoptively transferred naïve CD8+ T cells i.v. and the first dose of the virus (2.6×107 
PFU i.t.) were given on day 7 (when tumors reached approximately 100mm3). Second dose of the same 
amount of virus only was given on day 10. Treatment groups are: 1. vMyx-IL15Rα-tdTr i.t. + CD8+ T cells 
i.v., 2. vMyx-IL15Rα-tdTr i.t. + HBSS i.v., 3. PBS i.t. + CD8+ Tcells i.v., 4. PBS i.t. + HBSS i.v. Total 
number of mice were 4 per group, with the exception of n=3 for vMyx-IL15Rα-tdTr only treatment group. 
(A) Growth of individual tumors. Dashed lines designate time of virus treatment (B) Kaplan–Meier survival 
curve of the same experimental subjects. 
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Figure 3.2 – Survival of RAG1-/- mice with intracranial B16-SIY treated with vMyx-IL15Rα-tdTr 
and 2C T cells. RAG1-/- mice were implanted with unilateral B16-F10 tumor cells into the right ventral 
striatum. On day 5, mice were treated with a single dose of 1x106 PFU vMyx-IL15Rα-tdTr i.t. On day 6, 
5x106 activated 2C T cells were adoptively transferred i.v. to the tumor-bearing mice. Treatment groups 
are: 1. vMyx-IL15Rα-tdTr i.t. + 2C T cells i.v., 2. vMyx-IL15Rα-tdTr i.t. + HBSS i.v., 3. PBS i.t. + 2C 
Tcells i.v., 4. PBS i.t. + HBSS i.v. Kaplan–Meier survival curve; N=4 per group (* - p<0.05 for vMyx-
IL15Rα-tdTr/HBSS group compared to the PBS/HBSS treated group) 
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Figure 3.3 – tdTomato expression in the B16-SIY brain tumor sections of RAG1-/- mice 7 days after 
treatment with vMyx-IL15Rα-tdTr intratumorally. RAG1-/- mice were implanted with B16-SIY tumor 
cells unilaterally into the right ventral striatum. Five days later mice were treated by a single dose of vMyx-
IL15Rα-tdTr i.t. On day 5, mice were treated with a single dose of 1x106 PFU vMyx-IL15Rα-tdTr i.t. On 
day 6, 5x106 activated 2C T cells were adoptively transferred i.v. to the tumor-bearing mice. On day 12, 
mice were euthanized; brains were fixed, frozen in embedding media, and cryosectioned. Representative 
brain tumor sections are shown: (A) vMyx-IL15Rα-tdTr i.t. + 2C T cells; (B) vMyx-IL15Rα-tdTr i.t. + 
HBSS i.v.; (C) PBS i.t. + HBSS i.v. Red – tdTomato fluorescent protein; Blue – DAPI. 
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Figure 3.4 – Recombinant plasmid for modifying WT myxoma virus and generating vMyx-SIY-tdTr 
(pBS-SIY-tdTomato). Plasmid pBS-SIY-tdTomato (5780bp) is based on the pBluescript backbone on 
which M135 and M136 partial viral gene sequences are flanking genes for (SIYRYYGL)3-9 amino acid 
linker- tdTomato fluorescent protein transcription unit, under control of the vvSynE/L poxviral promoter. 
The expression cassette is flanked by partial viral gene sequences for the purpose of being transfected into 
the WT vMyx-Lau virus genome between genes M135 and M136. 
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Figure 3.5 – B16-F10 cells transiently transfected with pBS-SIY-tdTomato and infected with a 
poxvirus (MVA) express tdTomato fluorescent protein. B16-F10 cells in 6-well culture plates were 
transfected with plasmid DNA; 9h later, cells were infected with MVA at MOI=5. Treatment groups 
(Plasmid + Virus) are: 1. pBS-SIY-tdTomato + mock; 2. pBS-IL15Rα-IL15-tdTomato + MVA; 3. pBS-
SIY-tdTomato + MVA. Cells were imaged at (A) 12 h p.i. and (B) 36 h p.i. Top and bottom panels present 
bright-field and fluorescent image, respectively. Red fluorescence– tdTomato  
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Figure 3.6 – Flow cytometry detection of tdTomato expressed by B16-F10 cells transiently transfected 
with pBS-SIY-tdTomato and infected with MVA. B16-F10 cells in 6-well culture plates were transfected 
with plasmid DNA; 9h later, cells were infected with MVA at MOI=5. Treatment groups (Plasmid + Virus) 
are: 1. pBS-SIY-tdTomato + mock; 2. pBS-SIY-tdTomato + MVA; 3. pBS-IL15Rα-IL15-tdTomato + 
MVA. Cells were trypsinized, washed and analyzed for tdTomato expression in the FL2 channel. (A) 12 h 
p.i. (B) 36 h p.i. Percentages in all histogram legends indicate fraction of gated cells in the designated M1 
marker. 
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Figure 3.7 – Detection of Kb and Kb-SIY on B16-F10 and B16-SIY cells transiently transfected with 
pBS-SIY-tdTomato and infected with MVA. B16-F10 cells in 6-well culture plates were transfected with 
plasmid DNA; 9h later, cells were infected with MVA at MOI=5. Treatment groups (Plasmid + Virus) are: 
1. untreated cells; 2. no plasmid + mock 3. pBS-SIY-tdTomato + mock OR no plasmid + MVA; 4. pBS-
SIY-tdTomato + MVA . At 12h p.i., cells were trypsinized, washed and stained for the expression of mouse 
MHC Class I molecule with anti-Kb-APC and for the Kb-SIY complex using biotinylated soluble high-
affinity TCR, m67 followed by Streptavidin-APC. (A) Kb on B16-F10 (B) Kb on B16.SIY (C) Kb-SIY on 
B16-F10 (D) Kb-SIY on B16.SIY. Percentages in all histogram legends indicate fraction of gated cells in 
the designated M1 marker 
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CHAPTER FOUR 
IMMUNOTHERAPY AND GRAFT-VERSUS-HOST DISEASE (GVHD) 
4.1 Introduction 
Recent clinical trials with adoptive cell transfer (ACT) immunotherapies for cancer have shown promising 
results, most notably improving cure rates for metastatic melanoma [1]. Genetic engineering of T cells to 
express conventional α/β T cell receptors (TCRs) or chimeric antigen receptors (CARs) provides an 
opportunity to make ACT possible without the need to isolate and expand tumor-reactive T cells from 
individual patients [2]. In addition, TCRs or CARs can be used to redirect either CD4+ helper T cells or 
CD8+ cytotoxic T cells (CTLs) [3]. 
Despite successes with ACT, there are safety concerns associated with gene therapy with genetically 
engineered T cells. Major safety concerns include: choice of an effective and safe target for immunotherapy; 
potential toxicities associated with the introduced novel TCR; and choosing an appropriate adjuvant 
strategy to enhance clinical efficacy of TCR gene therapy of cancer [4]. An ideal target antigen for TCR 
gene therapy should have a high degree of tumor-specific expression in order to limit the chances of damage 
to normal tissues [4]. It should also be preferably expressed on tumor-initiating cancer stem cells [5] and it 
should have an essential role in maintaining the malignant phenotype in order to minimize the risk of tumor 
escape. 
A graft-versus-host reaction is also possible with adoptive T cell therapy. In graft-versus-host reactions, an 
immune attack is directed by the donor cells against normal host tissue. Clinical presentation in humans is 
usually associated with hematopoietic stem cell transplantation (SCT) for the treatment of cancers such as 
leukemia [6]. Acute GVHD (reaction within 100 days of graft transfusion) is generally accompanied by 
tissue damage of the skin, liver, and the gastrointestinal tract while chronic GVHD (reaction delayed for 
more than 100 days) targets a wide array of organs and can bear similarities with autoimmune disorders 
[7]. The current standard of care for GVHD prevention after SCT includes combined administration of 
tacrolimus and methotrexate; however severe GVHD is a major cause of morbidity and mortality following 
SCT [8].  
GVHD-like symptoms observed in our studies and elsewhere are associated with the CD4+ subpopulation 
of T lymphocytes. Physiologically, CD4+ T cells recognize peptides presented in the context of MHC class 
II molecules on the surface of antigen presenting cells (APCs). In animal models of GVHD, CD8+ T cells 
require interaction with cognate antigen to produce GVHD, but CD4+ T cells do not require cognate antigen 
[9]. Similarly, transfer of CD4+ T cells of undefined specificity is used as an animal model of colitis [10]. 
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With the advent of genetically engineered T cells, it is possible to redirect CD4+ cells to recognize peptides 
presented by class I MHC molecules, broadening the scope of adoptive cell therapy. Inclusion of CD4+ 
cells help with primarily cytotoxic CD8+ cells improves the therapeutic effect of ACT in many models [11] 
and in the clinic [12] [13]. However this could increase the risk of GVHD. Fine tuning the benefits of CD4+ 
cell help and undesirable side effects will be a necessity in ACT that aims to combine two T cell populations.  
We have encountered GVHD-like symptoms in our laboratory as a side effect of cancer therapy with 
genetically engineered TCRs introduced into CD4+ T lymphocytes [Soto CM, unpublished data]. Briefly, 
RAG1-/- mice with melanoma or glioma tumors expressing the SIY antigen treated with 2C and m33 TCR 
transduced T cells developed treatment related symptoms several weeks after ACT. Symptoms included 
progressive decreased motility and activity, skin lesions involving the eye, ears and tail, hunched posture, 
and diarrhea. Immunostaining for CD3+ cells showed an abnormal abundance of T lymphocytes dispersed 
throughout the ear dermis of mice. Histopathological findings included abnormal leukocyte infiltrates in 
the lungs, livers, stomach, and the small intestine, strongly indicative of GVHD pathology [7].  
The goal of this study was to better understand the mechanisms involved in inducing GVHD, in order to 
improve the outcome of TCR gene-modified T cell therapy while maintaining effective antitumor 
responses. In order to dissect the cause of the symptoms in mice that received genetically modified T cells, 
we were interested in testing the following hypotheses: 1) GVHD symptoms are dependent on SIY antigen 
expression in the tumor/tissue; 2) GVHD symptoms are affected by the affinity of the TCR transduced into 
CD4+ cells; 3) Regulatory T cells (Tregs) have a protective role in GVHD symptom manifestation.  
To test these hypotheses in a mouse model we used a TCR called 2C, which is derived from a well-
characterized CD8+ 2C T cell clone that was originally isolated over 30 years ago by Dr. David Kranz [14]. 
The 2C TCR recognizes and binds several defined peptide antigens bound to either allogeneic H-2Ld or 
syngeneic H-2Kb class I MHC molecules [15]. In the context of syngeneic class I MHC Kb, 2C cells 
recognize foreign peptide SIY (SIYRYYGL) with an affinity of 30 μM. In 2002, a high affinity TCR variant 
of 2C called m33 was isolated in the Kranz lab using the yeast display technique [16]. m33 recognizes SIY-
Kb with an affinity of 30 nM, and it is CD8 co-receptor independent [17]. Through TCR gene transfer, it is 
possible to redirect CD4+ cells to recognize peptides presented by MHC class I molecules. 
There are many useful reagents related to this well-defined system. 1b2, a monoclonal antibody against the 
2C TCR, can be used to identify 2C T cells by flow cytometry or immunohistochemistry. 2C TCR 
transgenic mice on the C57BL/6 background express the 2C TCR on approximately 80% or their CD8+ T 
cells. Tetramer SIY-Kb can be used to detect expression of both 2C and m33 TCR on the cell surface.   
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4.2 Materials and Methods 
Animals 
C57BL/6 and C57BL/6 RAG1-/- mice originally purchased from The Jackson Laboratory (Bar Harbor, ME, 
USA) were maintained as colonies and housed in the animal facilities at the University of Illinois. Mice 
were used in experiments when they were 2-5 months old. All animal studies were approved by the 
Institutional Animal Care and Use Committee at the University of Illinois. 
Activation and retroviral transduction of primary T cells 
T cells were obtained from spleens of C57BL/6 mice and prepared into a single-cell suspension. 
Erythrocytes were lysed with ammonium chloride (ACK) buffer and CD4+ T cells isolated by magnetic 
sorting using the Mouse CD4+ T Cell Isolation Kit II (MACS Miltenyi Biotec, Germany). T cell 
transduction was performed as described in Soto et al. [18]. Plat-E retroviral packaging cells [19] were 
plated at 4 x 106 cells/dish on a poly-L-Lysine (Sigma) coated 10 cm petri dish and cultured for 24 h. Plat-
E cells were transfected with 2C or m33 TCR gene, cloned into the pMP71 vector (from myeloproliferative 
sarcoma virus, MPSV) as 2C beta chain-P2A-2C alpha chain using NotI at the 5'-end and EcoRI at the 3'-
end [20]. The 2C TCR gene was codon optimized for expression in murine cells. Plat-E cells were 
transfected with 40 μg vector DNA, Lipofectamine 2000 (Invitrogen) and Opti-MEM (Invitrogen) for 4 h, 
after which the DNA-transfection mixture was aspirated and 6 ml of cell culture media added to each plate. 
Viral supernatant was harvested 48 h after transfection, passed through a 0.45 μm syringe filter and 50 μl 
of Lipofectamine 2000 added per 6 ml of viral supernatant.  
1 x 106 T cells per well were activated with anti-CD3 and anti-CD28 coated beads (Dynabeads, Invitrogen) 
and 30 U of recombinant mouse IL-2 (Roche) in a 24 well plate for 24 h. Following activation, Dynabeads 
were magnetically removed from T cells and cells were transferred into a 24-well plate coated with 
Retronectin at 15 μg/mL (Takara, Japan). In each well, 1 x 106 T cells in 1mL of T cell media were mixed 
with 60U of recombinant murine IL-2 and 1mL sterile 2C or m33 TCR viral supernatant from transfected 
Plat-E cells. The plate was centrifuged at 2,000 rpm at 30°C for 1 h. Following centrifugation, cells were 
incubated at 37°C in 5% CO2 in a humidified incubator and a second transduction was repeated 24 h later. 
Flow cytometry analysis 
Lymphocytes from spleens and lymph nodes of mice were prepared by mechanical tissue dissociation 
through nylon mesh followed by ACK buffer lysis of erythrocytes. Single-cell suspensions were stained for 
flow cytometry with following reagents: CD4-AlexaFluor647 (BD Pharmingen), Vβ8.1/8.2-PE (BD 
Pharmigen) and 1b2-biotin (Kranz Lab) antibodies; SIY-Kb-PE tetramer (Kranz Lab) and Strepavidin-APC 
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(Invitrogen). All reagents were used at final concentration of 10 μg/ml for 1 hr at 4°C, and washed with 
with 0.5% PBS/BSA in between staining steps. Cells were analysed on the Accuri C6 instrument and FCS 
Express software. 
Tissue sections and immunostaining 
After the mice were euthanized, their ears, parts of intestines and lymph nodes were isolated and snap-
frozen in OCT medium for cryosectioning and immunostaining. Eight µm cryosections were taken. Primary 
antibodies used for staining were: rabbit anti-CD3 (Abcam, Cambridge, MA) and rat anti-FoxP3 
(eBioscience, San Diego, CA). Secondary antibodies used: donkey anti-rabbit-DyLight 488 and donkey 
anti-rat-DyLight 594 (Jackson ImmunoResearch, West Grove, PA). For immunostaining, slides were fixed 
in cold 95% ethanol and blocked with Superblock (Thermo Scientific, Rockford IL). Sections were then 
incubated with a primary antibody in PBS + 20% glycerol (PBSG) overnight, washed with PBS + 0.1% 
Tween-20 (PBST), and incubated with secondary antibody in PBST for 4 h. Slides were washed and briefly 
incubated with DAPI (Invitrogen, Carlsbad, CA). Control slides omitting the primary antibody were 
negative for DyLight 594 or DyLight 488. Images were obtained with an Olympus BX-51 microscope at 
20x magnification. 
Data Analysis 
GraphPad Prism software (La Jolla, CA) was used for all statistical analyses and graph presentation. 
Symptom onset data were recorded from the time of the adoptive transfer until symptoms were first 
observed and were plotted using a Kaplan-Meier curve. Significance was considered P<0.05. 
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4.3 Results 
Onset of GVHD-like symptoms is independent of the SIY antigen 
Previous occurrences of GVHD-like symptoms observed in our laboratory were a side effect of therapy 
with T cells genetically modified to recognize the model antigen SIY present on tumors in mice. Treatment 
with T cells transduced to express TCRs that are specific for SIY peptide resulted in prolonged survival in 
melanoma and glioma models [18] [Soto CM, unpublished data]. However, it was unclear whether the 
presence of the foreign SIY antigen was necessary to drive the GVHD-like side-effects caused by the T 
cells.  
In order to test this requirement, tumor-free RAG1-/- mice were injected with CD4+ T cells transduced either 
with 2C TCR, m33 TCR or mock transduced (n=3 per group). CD4+ cells were enriched from primary 
lymphocytes isolated from C57BL/6 mice. Cells were then activated and retrovirally transduced with the 
SIY-specific 2C TCR, its high-affinity version m33 TCR or mock transduced (Figure 4.1). Approximately 
6.5 x 106 T cells were administered through tail vein injection per mouse.  
Mice were monitored for 70 days for development of GVHD-like symptoms (skin lesions associated with 
ears and face, tails and limbs, ulceration, weight loss). After 70 days, mice were injected with 10 µg of SIY 
peptide i.p., which is a treatment that activates 2C T cells in vivo [21]. One mouse from each group was 
left as an untreated control, and the rest were further observed for signs of GVHD-like symptom 
progression. 
By day 70, when challenge with SIY peptide i.p. was planned and executed, GVHD symptoms were 
observed in some of the treated mice (Figure 4.2). Figure 4.2A shows a timeline of the symptom onset per 
group in the Kaplan–Meier curve format. There was a significant effect of TCR transfection on symptom 
onset time (p < 0.01). Images of experimental animals are shown in Figure 4.2B, and GVHD lesions are 
evident in affected mice. Table 4.1 summarizes the details of symptom onset, symptom description and 
experimental manipulation. Development of GVHD symptoms in experimental mice was independent of 
the presence of the SIY antigen in the system: symptoms developed without SIY involvement and did not 
worsen after exposure to SIY.  
Affinity of the transduced TCR as a factor in manifestation of GVHD-like symptoms 
From previous experiments, it was clear that onset of GVHD symptoms was correlated with the transfer of 
genetically modified CD4+ T cells. However, the contribution of the affinity of the transferred TCR for its 
target was inconclusive. In our experiment, in the 2C CD4+ group, all three animals developed symptoms, 
and one animal had to be euthanized due to 25% weight loss at day 40 post ACT. In the m33 CD4+ group, 
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two out of three animals developed lesions on the ears. In the mock transduced group, no GVHD symptoms 
were observed (Figure 4.2). Treatment with CD4+ T cells transduced with 2C TCR showed a trend towards 
quicker development and worse manifestation of GVHD symptoms as compared to m33 TCR-transduced 
cells. This is consistent with earlier observations in tumor-bearing mice. Our results suggest that GVHD 
symptoms observed in our model are TCR and self-antigen dependent, but the influence of affinity of the 
transferred TCR requires further investigation. 
TCR transduced CD4+ cells persist in mice with GVHD-like symptoms 
After the mice were euthanized, we examined the persistence of transferred CD4+ cells in RAG1-/- mice. 
One mouse had to be euthanized early due to the severity of GVHD symptoms (day 40 post ACT), while 
the other were kept for 4-5 months after the cell transfer.  
In order to test initial transduction efficiency of murine CD4+ T cells with 2C and m33 TCRs, we stained 
the cells with SIY-Kb tetramer that binds to both 2C and m33 TCRs (Figure 4.1A), as well as with the 
antibody for Vβ8.1,8.2 TCR chains present in both transduced TCRs (Figure 4.1B). According to the SIY-
Kb tetramer binding, transduction efficiency was 36% and 32% for 2C and m33, respectively in CD4+ cells 
(background staining of mock transduced cells shows 1%). Similar values are obtained from staining for 
presence of Vβ8.1,8.2 TCR chain. 41% of primary murine lymphocytes express the same TCR Vβ, as 
evident in the histogram of mock transduced cells.  
Figure 4.3 shows splenocytes from the mouse 1682 that received 2C CD4+ T cells and had to be euthanized 
due to the severity of symptoms 40 days after cell transfer. Cells are stained with 1b2, a clonotypic antibody 
for 2C TCR and show persistence of substantial amount of 2C+ cells (approximately 60% of all CD4+ 
splenocytes) at this early time-point (Figure 4.3A). There were 75% Vβ8.1,8.2 TCR positive splenocytes 
in mouse 1682 (Figure 4.3B), which correlates well with 72% Vβ+ transferred 2C TCR transduced T cells 
(Figure 4.1B). 
When the experiment was terminated after 5 months, splenocytes isolated from remaining mice were also 
evaluated for persistence of transferred TCRs, by staining with SIY-Kb tetramer, 1b2 clonotypic antibody 
for 2C TCR and the more general Vβ8.1,8.2 TCR stain (Figure 4.4). Tetramer stain of the CD4+ splenocyte 
subset was positive for 24% and 16% cells in the 2C group mice and for 26%, 31% and 17% cells in the 
m33 group mice (background staining of mock transduced cells was ~2%) (Figure 4.4A). Stain with 1b2, 
expected to stain only 2C TCR, stained 43% and 36% CD4+ cells in two mice from the 2C group, with 
background staining of about 6% (Figure 4.4B). Vβ+ fraction of all splenocytes was 8% and 10% for mice 
that received mock transduced cells, 19% and 25% for 2C TCR recipients and 14%, 27% and 21% for m33 
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TCR recipients (Figure 4.4C). These results show sustained persistence of transferred genetically modified 
T cells, as far as 5 months after adoptive transfer.  
Presence of regulatory T cells in organs of treated mice shows no strong correlation with symptom 
presence  
We hypothesized that regulatory T cell phenotype (Treg) may have a protective role in the context of GVHD 
symptom development in our model. We evaluated the presence of Tregs in the organs affected by GVHD 
symptoms by immunohistochemistry. Frozen sections of lymph nodes, ears and intestines were sectioned 
and stained for the universal T cell marker, CD3, as well as for the Treg marker, transcription factor FoxP3. 
Representative sections of analyzed organs are presented in Figure 4.5; the top panels show examples of 
sections from mice affected by GVHD symptoms, and the bottom panels are from mice that remained 
symptom-free. In our sample, there was no strong correlation of Treg presence and protection from GVHD 
symptom onset. Lymph node sections of all analyzed mice were abundant with FoxP3+ cells (Figure 4.5A, 
red). Intestine from 1683, the protected mouse from the m33 TCR group, suggested an increased Treg 
infiltration compared to other samples (Figure 4.5B). However, most of the Treg infiltration in the ears was 
observed in 1692, a 2C recipient mouse with noticeable, albeit controlled ear damage. 
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4.4 Discussion 
Our results suggest that GVHD-like symptoms observed in our model are TCR and self-antigen dependent. 
Symptoms did not manifest in mice treated with mock transduced CD4+ cells, and were independent of 
TCR-specific antigen (SIY) expression in the host. There was a trend towards more severe and earlier onset 
symptom manifestation associated with treatment with cells transduced with the wild type TCR (2C) 
compared to the high affinity TCR (m33). This is consistent with prior observations in our laboratory, in 
the context of tumor-bearing mice [Soto CM, unpublished data]. In these prior studies, effects appeared to 
be more predominant with 2C TCR in CD4+ T cells than m33 in CD4+ T cells, and the most severe GVHD 
clinical signs were exhibited in mice which received a combination treatment of CD8+ and CD4+ cells, 
suggesting that CD8+ T cells might exacerbate symptoms induced by CD4+ cells [Soto CM, unpublished 
data]. 
Experimental evidence in mice has shown that new self-reactive T-cell specificities created upon the 
formation of mixed TCR dimers following transfection with TCR genes can result in autoimmune 
destruction [22] [23]. This pathology, termed “TCR gene therapy-induced graft-versus-host disease,” only 
becomes apparent under conditions in which the TCR-modified T-cell response is vigorous [22]. Since 
similar findings have not been found (or reported) in ACT clinical trials done in humans, speculations were 
present that it is a problem unique to mice [24]. It is possible however that the problem will occur with 
increasing the in vivo function of TCR-modified T cells in humans, and it has been demonstrated with 
human cells in vitro [23]. Two TCR engineering strategies can be used to combat the observed mixed TCR 
dimer-dependent GVHD symptoms in mice. First one is the use of TCR engineered with an additional inter-
chain disulphide bond [25], and the other one is linking TCR-α and TCR-β genes with a virus-derived P2A 
element [26]. These strategies can limit or prevent GVHD symptoms in mice after TCR gene transfer [22] 
and might also enhance the antitumor efficacy of TCR gene therapy in mice [4]. GVHD-like symptoms 
observed in our lab are unlikely due to TCR α and β chain mis-pairing (formation of “mixed TCT dimers”) 
as these TCRs have been codon optimized, contain the P2A cleavage site, and the extra C region cysteines 
that have been shown to mitigate the mis-pairing problems [4]. 
Given that many studies have shown that transfer of CD4+ T cells from C57BL/6 mice into RAG1-/- mice 
induces GVHD-like symptoms [9] [10], the surprising result in our studies was the lack of GVHD-like 
symptoms in mice treated with mock transfected T cells. CD4+ T cells are able to induce GVHD symptoms 
even in mice that do not express MHC II [9]. The cellular interactions between CD4+ T cells and 
macrophages may be critical for the induction of GVHD; for example, manipulation of TLR-4 agonists in 
the gut (by altering the intestinal flora) affects whether CD4+ T cells induce GVHD-like symptoms or have 
no effect [27]. Other studies have shown that polymorphisms in macrophage pattern recognition receptors 
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affect whether CD4+ T cells induce GVHD-like symptoms. Interestingly, the subtype of CD4+ cells that 
most effectively induces intestinal damage is the CD45RBhigh subset, which is characteristic of naïve CD4+ 
T cells [10]. Co-injection of CD45RBlow CD4+ T cells prevents the induction of symptoms [28]. Perhaps 
there is some low affinity interaction of the transfected TCR with self-antigens that allows maintenance of 
a more naïve phenotype, which does not occur with the mock transfection. 
We were unfortunately unable to shed much light on the cause of the GVHD-like symptoms in mice treated 
with CD4+ transfected T cells. Injection of CD4+ T cells has been used to create models of colitis and 
GVHD-like symptoms for more than 20 years, and the roles of multiple cell types in the response are still 
being investigated. 
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4.6 Figures 
 
Figure 4.1 – Phenotype of transduced CD4+ splenocytes prior to adoptive transfer to RAG1-/- mice. 
CD4+ T cells were isolated by magnetic sorting from C57BL/6 mice splenocytes and retrovirally 
transduced with 2C TCR, m33 TCR or mock transduced. (A) Dot plots showing TCR-transduced cells 
positive for CD4 and Kb-SIY tetramer, which stains both 2C and m33 TCR; Histograms showing the Kb-
SIY tetramer stain for all conditions. (B) Dot plots showing TCR-transduced cells positive for CD8 and 
TCR β chain Vβ8.1,8.2, which is present in both 2C and m33 TCR, and some endogenous TCRs; 
Histograms showing the Vβ stain for all conditions. Percentages in tables indicate fraction of gated cells in 
the designated M1 marker (cells considered positive). 
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Figure 4.1 (cont.) – Phenotype of transduced CD4+ splenocytes prior to adoptive transfer to RAG1-/- 
mice. 
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Figure 4.2 – GVHD symptoms as a result of auto-reactive CD4+ T cells transduced with different 
TCRs in RAG1-/- mice without tumors. RAG1-/- mice were injected with CD4+ cells transduced with 2C 
TCR, m33 TCR or mock transduced. Mice were monitored for onset of GVHD symptoms (skin lesions on ears, 
face, tails and limbs, ulceration, weight loss). (A) Kaplan–Meier curve presenting percent of mice that have 
developed GVHD symptoms. Numbers on graph indicate median day of symptom onset post-adoptive cell 
transfer. Number of mice was 3 per group. (B) Images of physical GVHD presentation on mice following 
transduced CD4+ T cell injection. All animals were euthanized on day 127 or day 165 post-cell transfer, apart 
from one animal that had to be sacrificed at day 40 because of weight loss. GVHD signs include skin lesions on 
ears and head (shown), tails and limbs of mice (not shown). Underlined mouse numbers indicate animals that 
developed GVHD symptoms.  
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Table 4.1 – Summary of GVHD symptoms in RAG1-/- mice following transfer of transduced CD4+ T cells 
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Figure 4.3 – Phenotype and persistence of T cells transduced with 2C TCR in the mouse with most 
acute GVHD symptoms at day 40 post adoptive transfer. On day 40 post adoptive transfer, mouse 1682 
that got CD4+ T cells transduced with 2C TCR needed to be euthanized because of weight loss. The spleen 
was isolated and persistence of transferred cells was analyzed. (A) Dot plot showing CD4 and 2C TCR 
positive cells (stained by clonotypic 1b2 antibody); histogram is gated on CD4+ cells. (B) Dot plot showing 
CD4 and TCR Vβ8.1,8.2 levels; histogram is gated the same way as the dot plot. Percentages in tables 
indicate fraction of gated cells in the designated M1 marker (cells considered positive). 
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Figure 4.4 – Phenotype and persistence of transduced T cells in mice 4 and 5 months post ACT. On 
days 127 or 165 post adoptive transfer, mice that got CD4+ T cells transduced with 2C, m33 or mock TCR 
were euthanized, their splenocytes were isolated and tested for persistence of transferred cells. Histograms 
from all remaining mice are overlaid for each stain. Black histograms – mock, red histograms – 2C, blue 
histograms – m33 (A) Kb-SIY tetramer stain of cells from all remaining mice. Histograms are gated on 
CD4+ cells. (B) 1b2 (clonotypic antibody for 2C TCR) stain of cells from all remaining mice. Histograms 
are gated on CD4+ cells. (C) TCR Vβ8.1,8.2 levels of cells from all remaining mice. Histograms are gated 
on all lymphocytes. Percentages in tables indicate fraction of gated cells in the designated M1 marker (cells 
considered positive). 
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Figure 4.5 – Presence of regulatory T cells in organs of mice that received transduced T cells. RAG1-
/- mice were injected with CD4+ cells transduced with 2C TCR, m33 TCR or mock transduced. Mice were 
monitored for onset of GVHD symptoms (skin lesions on ears, face, tails and limbs, ulceration, weight 
loss). On days 127 or 165 post adoptive transfer, mice were euthanized, their lymph nodes, parts of intestine 
and ears were isolated, frozen in embedding media, and cryosectioned. Organ sections were immunostained 
for CD3 surface marker (T cells) and FoxP3 transcription factor (Tregs). Representative organ sections are 
shown; top panels show examples of sections from mice affected by GVHD symptoms, and bottom panels 
are from mice that remained symptom-free. Treatment group is indicated above the image, and mouse ID 
is embedded in the image. (A) Lymph node. (B) Intestine. (C) Ear. Green – CD3-positive, red – FoxP3-
positive. Scale bar = 50 micrometers. 
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Figure 4.5 (cont.) – Presence of regulatory T cells in organs of mice that received transduced T cells. 
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Figure 4.5 (cont.) – Presence of regulatory T cells in organs of mice that received transduced T cells. 
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CHAPTER FIVE 
CONCLUSION 
Immunotherapies and especially adoptive cell transfer are emerging as therapeutic modalities with potential 
for high impact in treatment for cancers and other chronic diseases. It is likely that immunotherapy, like 
other anti-cancer strategies before it, will benefit from some form of combination therapy in order to achieve 
the greatest clinical outcome. Oncolytic viral therapy, the use of cancer-specific viruses to target and kill 
cancer cells, is a therapeutic modality that is well suited to deliver and augment immunotherapeutic 
strategies. 
The aim of my thesis was to improve efficacy and safety of antitumor immunotherapy. We explored several 
approaches to achieve this goal. Firstly, we have analyzed antitumor effects of an oncolytic myxoma virus 
armed to secrete an immunostimulatory protein at the tumor site. In order to do that, we engineered a new 
recombinant myxoma virus (vMyx-IL15Rα-tdTr), which expresses IL15Rα-IL15 fusion protein. We 
described the therapeutic effects observed with the new virus in a mouse model of aggressive melanoma, 
B16-F10, in immune deficient as well as immune competent mice. Treatment with the novel virus resulted 
in a significant survival benefit for the treated group compared to the controls, and immunohistological 
analysis suggested that both the innate and adaptive components of the host immune system play a role in 
the antitumor effect. Our work contributes to the growing body of evidence that using armed viruses to 
boost antitumor immune response is a feasible strategy for complementing immunotherapies. 
In order to further expand this approach, we explored the use of myxoma virus for increasing tumor antigen 
presentation at the tumor site. Tumor-antigen specific therapies face the challenge of selecting for 
subpopulations of cancer cells that no longer express the target and cause reemergence of the tumor. We 
designed a model-tumor antigen expressing myxoma virus, for the purpose of enhancing combination 
therapy with antigen-specific T lymphocytes. We hypothesize that the combination of the viral effect of 
enhancing the attenuated immune response and increasing the presence of T cell specific antigen in the 
tumor would lead to tumor elimination. 
With the emergence of adoptive T cell therapy as a more widely used treatment modality, the safety of this 
groundbreaking approach will be a major concern. Severe side effects of target-specific T cell therapy that 
are emerging in clinic due to cross-reactivity of transferred cells with normal host tissues were 
foreshadowed by preclinical studies. We have observed unexplained graft-versus-host like symptoms as a 
side effect of adoptive T cell cancer therapy in mice in our laboratory when CD4+ T cells are used. In order 
to gain insight into the cause of the symptoms, we examined the outcome of transfer of genetically modified 
T cells to tumor-free recipients and analyzed the underlying pathology. There is still a lot left to investigate 
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in this phenomenon: the role of multiple cell types in the response, as well as the contribution of the genetic 
modification and of cell receptors engineered for higher affinity.  
Together, these studies have made a significant contribution to the general field of combination 
immunotherapy. The most notable result of my work is proof of principle that viral delivery of IL15Rα-
IL15 can improve the antitumor effect, and cause dramatic recruitment of immune cells to the tumor site. 
A combination of different delivery vehicles for the IL15Rα-IL15 fusion protein should be explored in the 
future. Also, viral delivery could be improved by combination treatment with drugs such as rapamycin. In 
order to make the most out of the viral specificity for the cancer cells, improving systemic delivery of the 
virus for treatment of metastatic disease would be a big improvement in this proposed strategy.  
 
